fluorouracil has been researched along with Ovarian Neoplasms in 505 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 9.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 9.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "Four patients with pseudomyxoma peritonei associated with mucinous tumors of the ovary were treated with cytoreductive surgery followed by intraperitoneal (IP) 5-fluorouracil (5-FU)." | 7.68 | Pseudomyxoma peritonei: treatment with intraperitoneal 5-fluorouracil. ( Given, FT; Kemp, GM; Nasr, MF, 1993) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 7.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| "Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells." | 5.37 | Novel activity of acriflavine against colorectal cancer tumor cells. ( Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L, 2011) |
| "Irofulven has demonstrated potent activity against a broad range of solid tumors in both cellular and xenograft models and has shown promising activity in clinical trials." | 5.32 | Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. ( Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ, 2003) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 5.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| "Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently." | 5.05 | Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF). ( Carmo-Pereira, J; Costa, FO; Henriques, E; Ricardo, JA, 1981) |
| "Two consecutive studies were undertaken in patients with advanced adenocarcinoma of the ovary to compare melphalan, adriamycin and 5-fluorouracil (MAF) with cyclophosphamide, adriamycin and 5-fluorouracil (CAF)." | 5.05 | Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens. ( Aroney, RS; Dalley, DN; Levi, JA, 1981) |
| "From 1977 until 1980, 179 patients with newly diagnosed FIGO stages IIB, III or IV ovarian adenocarcinoma were randomized in a two-armed clinical trial: dihydroxybusulfan (B) 600 mg/m2 p." | 5.05 | A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. ( Aabo, K; Dombernowsky, P; Hald, I; Hansen, HH; Hørbov, S; Lundvall, F; Nielsen, NC; Sørensen, BL; Sørensen, HM, 1985) |
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 5.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "Comparisons between the effects exerted by adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)-based polychemotherapy and endocrine treatment in premenopausal breast cancer patients are validly drawn in the presence of steroid hormone receptor responsiveness." | 4.81 | Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer. ( Hausmaninger, H; Jakesz, R; Samonigg, H, 2002) |
| "Oxaliplatin in combination with fluorouracil/folinic acid is an effective treatment option for patients with metastatic colorectal cancer, both as a first-line therapy and in patients refractory to previous chemotherapy." | 4.80 | Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. ( Clemett, D; Culy, CR; Wiseman, LR, 2000) |
| "Betulinic acid selectively inhibits the growth of ovarian carcinoma cell lines without affecting the normal cells." | 3.81 | Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. ( Dou, YC; Liu, JB; Wang, YJ, 2015) |
| "Uracil mustard and 5-fluorouracil (UM-FU) combination chemotherapy was used as one of the earliest combination chemotherapies in ovarian carcinoma from 1964 to 1971 at Yale New Haven Medical Center." | 3.79 | Uracil mustard and 5-fluorouracil combination chemotherapy: a historic record. ( Kohorn, EI, 2013) |
| "MTT assays revealed that tumor cells from ascites of primary and type II EOC were more sensitive to paclitaxel (PTX) and carboplatin (CBDCA) than relapse (p = 0." | 3.79 | In vitro chemosensitivity assay of ascites in epithelial ovarian cancer. ( Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y, 2013) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen)." | 3.73 | Oxaliplatin-related acute myelogenous leukemia. ( Carneiro, BA; Eldibany, M; Kaminer, L; Kaul, K; Locker, GY; Sreekantaiah, C, 2006) |
| " With the use of this assay, the authors determined dose-response curve in mouse fibroma cell line L929 treated with chemotherapeutic agents, and investigated the different in vitro responses of 6 ovarian carcinomas (5 from fresh tumor tissues, 1 from ascites) treated with etopside, cis-plating, 5-fluorouracil and adriamycin." | 3.70 | [An evaluation of adenosine triphosphate bioluminescence assay for tumor in vitro chemosensitivity testing]. ( He, B; Liu, S; Lou, J; Peng, Z; Tang, Q; Wang, H, 2000) |
| "The aim of this study was to demonstrate the value of the level of platinum in lymphocytes, plasma and saliva, in order to predict neutropenia during the same cycle after cisplatin chemotherapy." | 3.70 | [Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)]. ( Brès, J; Constans, B; Cupissol, D; Gau, F; Gory-Delabaere, G; Nouguier-Soulé, J, 1999) |
| "Four patients with pseudomyxoma peritonei associated with mucinous tumors of the ovary were treated with cytoreductive surgery followed by intraperitoneal (IP) 5-fluorouracil (5-FU)." | 3.68 | Pseudomyxoma peritonei: treatment with intraperitoneal 5-fluorouracil. ( Given, FT; Kemp, GM; Nasr, MF, 1993) |
| " 5-Fluorouracil (5-FU) was effective against only one bladder cancer xenograft among 6 cancer xenografts tested." | 3.68 | [Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice]. ( Adachi, S; Akaza, H; Ishitsuka, H; Kanazawa, K; Miwa, M; Nitta, K; Sekiguchi, F; Tokita, H, 1991) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 3.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| " Except for melatonin, all neuroendocrine hormones used in this study inhibited proliferation of KF cells derived from human serous cystadenocarcinoma of the ovary in a dose-dependent manner." | 3.67 | Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones. ( Iwano, I; Kato, K; Kikuchi, Y; Kita, T; Miyauchi, M, 1989) |
| "The adjuvant effect of calmodulin antagonists (W-5 and W-7) to 5-fluorouracil (5-FU) was studied by using two human cultured cell lines derived from ovarian adenocarcinoma." | 3.67 | Adjuvant effects of calmodulin antagonists to 5-fluorouracil on tumor cell proliferation and the mechanisms. ( Kato, K; Kikuchi, Y; Kizawa, I; Oomori, K, 1987) |
| "Following surgery for epithelial carcinoma of the ovary, FIGO stages IIc, III and IV, 110 patients received chemotherapy in one of four treatment regimens (Melphalan; Cyclophosphamide-Methotrexate-Fluoro uracil; Cyclophosphamide-Cisplatinum; Cyclophosphamide-Cisplatinum-Fluoro-uracil)." | 3.66 | [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)]. ( Aguilera, J; Breau, JL; Israël, L; Lepage, E, 1982) |
| "Squamous cell carcinoma is the most common malignant change." | 2.78 | Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution. ( Khemapech, N; Oranratanaphan, S, 2013) |
| "To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer." | 2.76 | [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011) |
| "Capecitabine is an oral chemotherapeutic agent, already used in breast and colon cancer." | 2.74 | A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. ( Beneduce, G; Breda, E; Di Maio, M; Forestieri, V; Gallo, C; Gebbia, V; Greggi, S; Lauria, R; Losito, S; Morabito, A; Pignata, S; Pisano, C; Scalone, S; Scaltriti, L; Sorio, R; Zagonel, V, 2009) |
| "Since the prognosis of recurrent ovarian cancer patients is still poor, we need to establish a useful treatment strategy to achieve their long-term survival." | 2.73 | Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience. ( Ebina, Y; Hosaka, M; Mitamura, T; Moriwaki, M; Ohba, Y; Sakuragi, N; Takeda, M; Todo, Y; Watari, H, 2008) |
| "Capecitabine was administered beginning at 2000 mg/m2/day orally in two divided doses with meals on a 21-day cycle: 14 days of capecitabine followed by a 7-day rest period." | 2.72 | A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. ( Atkinson, N; Bodurka, DC; Branham, D; Gershenson, DM; Jenkins, AD; Sun, CC; Verschraegen, C; Wolf, JK, 2006) |
| "Oral capecitabine is a highly active, well-tolerated and convenient treatment for breast and colorectal cancer." | 2.71 | A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. ( Kaye, SB; McMahon, L; Paul, J; Reed, N; Vasey, PA, 2003) |
| "The overall response rate in the 18 cervical cancer patients was 89% (78% complete, 11% partial)." | 2.69 | Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies. ( Fleming, G; Mundt, AJ; Quiet, C; Rotmensch, J; Waggoner, S, 1999) |
| " Only one patient required a dosage adjustment of cisplatin for a serum creatinine elevation >2." | 2.69 | Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. ( Braly, P; Doroshow, JH; Johnson, D; Kogut, N; Leong, L; Longmate, J; Margolin, K; McNamara, M; Morgan, RJ; Nagasawa, S; Najera, L; Raschko, J; Schinke, S; Shibata, S; Somlo, G, 2000) |
| "courses in 15 patients with cancer of different origins." | 2.68 | Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. ( Gabizon, AA; Gorodetsky, R; Mou, X; Vexler, AM, 1995) |
| " As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats." | 2.68 | [Chrono-chemotherapy and dose intensity]. ( Lévi, F, 1995) |
| "Lymphatic metastasis is one of the most important problems in the treatment of gynecologic malignancy." | 2.68 | [Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report]. ( Cao, Z; You, Z; Zhou, S, 1995) |
| "All patients had surgically documented minimal residual disease (1." | 2.68 | Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. ( Averette, H; Berek, JS; Blessing, JA; Braly, PS; Homesley, HD, 1995) |
| "We conclude that the French ovarian cancer protocol may represent a significant advance and that glucose potentiation may be more widely applicable as an adjunct to cancer chemotherapy." | 2.67 | Glucose effects in an ovarian cancer protocol of exceptional activity. ( Lin, JY; Scheim, DE, 1993) |
| "Vomiting was not consistently related to the excretion of either catecholamine." | 2.67 | Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. ( Börjesson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1994) |
| "5-Fluorouracil (5-FU) is an antimetabolite chemotherapy, which selectively functions at the S phase of the cell cycle." | 2.67 | Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer. ( Barnes, WA; Barter, JF; Burnett, AF; Jarvis, T; Potkul, RK, 1994) |
| "Twenty nine patients with ovarian cancer of common epitherial origin who had no evidence of disease proved by computed tomography after the initial operation and chemotherapy were studied." | 2.67 | [Evaluation of UFT administration in patients with ovarian cancer who had no evidence of disease after the initial therapy]. ( Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Nakayama, K; Shimizu, Y; Teshima, H; Yamauchi, K; Yokosuka, K, 1990) |
| "Consequently, SLO in the treatment of ovarian cancer is considered to be effective in the extirpation of residual cancer and in the early detection of cancer recurrence." | 2.66 | [Studies of second-look operations (SLO) in ovarian cancer]. ( Yuzawa, H, 1989) |
| " There were no differences in response to therapy or in survival between the patients treated with melphalan followed by 5-fluorouracil and then by methotrexate in high dosage and the patients treated with the same agents in combination." | 2.65 | Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. ( Boyes, DA; Dodds, DJ; Gerulath, A; Kirk, ME; Klaassen, DJ; Levitt, M; Miller, AB; Pearson, JG; Wall, C, 1980) |
| "Thirty-eight patients with an advanced ovarian cancer (FIGO stage III and IV) were randomly allocated to treatment, either with melphalan (M) or a combination of adriamycin, 5-fluorouracil and cyclophosphamide (CAF) to determine the effect on survival." | 2.65 | A controlled clinical trial in advanced ovarian cancer. ( Adams, M; James, KW; Johansen, KA; Rocker, I, 1982) |
| "The age adjusted death rate for ovarian cancer has remained unchanged for the past 20 years." | 2.64 | Advances in the staging and treatment of ovarian cancer. ( Fisher, RI; Young, RC, 1977) |
| " A total dosage of 17-23 g." | 2.64 | [Use of ftorafur for the treatment of 3d-4th stage]. ( Gutman, EKh; Osman, VI; Plaude, RK; Purinia, IZh; Tabachnik, BI, 1975) |
| "The main problem in ovarian cancer is late diagnosis." | 2.64 | Report on treatment of cancer of the ovary. ( Kuipers, T, 1976) |
| "We observed a case of multiple brain metastases in an EOC patient after complete response of a pelvic recurrence to platinum/paclitaxel chemotherapy." | 2.42 | Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. ( Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H, 2004) |
| "Among gynecologic cancers, ovarian cancer is treated with chemotherapy as a routine practice." | 2.41 | [Gynecologic cancer-evidenced based chemotherapy]. ( Ochiai, K, 2000) |
| "Capecitabine is a thymidine phosphorylase (TP)-activated oral fluoropyrimidine, rationally designed to generate 5-fluorouracil (5-FU) preferentially within tumors." | 2.41 | Vision of the future: capecitabine. ( Twelves, C, 2001) |
| "Case 2 was a 68-yo-female with an endometrial cancer recurrence." | 2.40 | [Anticancer drug-induced colitis--case report and review of the literature]. ( Abe, H; Ishiguro, K; Mitani, I; Tsunaga, N; Yamashita, S, 1997) |
| " This method was found to be accompanied by a good treatment compliance and high dose intensity due to significantly reduced toxic effects when CDDP was combined with several other agents." | 2.40 | [Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies]. ( Hasumi, K; Shimizu, Y, 1999) |
| "Altretamine is a National Cancer Institute-designated group C antineoplastic agent used in the treatment of advanced ovarian cancer." | 2.38 | Altretamine. ( Hansen, LA; Hughes, TE, 1991) |
| "Using established ovarian cancer cells lines as well as ovarian cancer cells isolated from a patient with high-grade drug-resistant ovarian carcinoma, we demonstrate that ovarian CSCs consistently express lower levels of NKG2D ligands (MICA/B and ULBPs) on their surfaces, a mechanism by which they evade natural killer (NK) cells' surveillance." | 1.91 | Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands. ( Hatefi, A; Li, G; Nikkhoi, SK, 2023) |
| "Alopecia was observed in 60% of patients." | 1.62 | Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021) |
| " After rAd-p53 treatment, one of the three relapsed ovarian cancers achieved complete remission(CR), one achieved partial remission (PR), and one was stable disease (SD); the treatment-naive patient was operated after rAd-p53 combined with neoadjuvant chemotherapy and achieved pathological CR." | 1.56 | Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer. ( Li, X; Qu, H; Xia, Y, 2020) |
| "Precision or personalized cancer medicine is a clinical approach that strives to customize therapies based upon the genomic profiles of individual patient tumors." | 1.48 | Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy. ( Benigno, BB; Clayton, EA; Huang, C; Matyunina, LV; McDonald, JF; McDonald, LD; Vannberg, F, 2018) |
| "MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy." | 1.48 | Acquired resistance to immunotherapy in MMR-D pancreatic cancer. ( Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD, 2018) |
| "miR-206 was down-regulated in ovarian cancer tissues compared to normal ovarian tissues." | 1.46 | [Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells]. ( DU, Y; Ling, C; Liu, S; Wang, Y; Zhang, FC, 2017) |
| "Ovarian cancer is the most lethal disease among gynecological malignancies." | 1.46 | Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G₂ Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells. ( Akiyama, M; Kitawaki, J; Sakai, T; Sowa, Y; Taniguchi, T; Watanabe, M; Yogosawa, S, 2017) |
| "However, ovarian cancer cells with ectopic expression of cyclin A1 demonstrated slowdown of proliferation and senescence-associated β-galactosidase activity." | 1.43 | Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells. ( Berkowitz, RS; Huang, KC; Muto, MG; Ng, MC; Ng, SK; Ng, SW; Welch, WR; Yang, J, 2016) |
| "Endometriosis was not independently associated with the prognosis of the OCCC patients, even when the tumor was confined to stage I." | 1.43 | Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions. ( Bai, H; Cao, D; Chen, J; Sha, G; Shen, K; Wang, Y; Yang, J; Yuan, F; Zhang, Z, 2016) |
| "We diagnosed recurrence of jejunal carcinoma in the ileum and right ovary." | 1.43 | [Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report]. ( Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Matsuda, C; Mizushima, T; Mori, M; Nishimura, J; Ohara, N; Satoh, T; Takahashi, H; Yamamoto, H, 2016) |
| "Paclitaxel sensitivity was also correlated with BAF57 expression, but without significance." | 1.42 | Expression of BAF57 in ovarian cancer cells and drug sensitivity. ( Hachisuga, T; Iwai, Y; Izumi, H; Kurita, T; Morimoto, Y; Nishio, K; Tsukada, J; Yamaguchi, T, 2015) |
| "The authors conclude that multiple synchronous neoplasms can be treated with individualized chemotherapeutic protocol with good efficacy and few adverse reactions." | 1.42 | [Individualized therapy of synchronous ovarian and colon cancers with lymph]. ( Bishr, AM; Deme, D; Nizar, J; Telekes, A, 2015) |
| "In conclusion, Rosi may reverse MDR of ovarian cancer cells by downregulating the Wnt/β-catenin pathway with the suppression of FZD1." | 1.42 | Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes. ( Hu, J; Jing, X; Li, W; Su, P; Wang, X; Wu, X; Zhang, H; Zhang, X; Zhou, G, 2015) |
| "Colon cancer in pregnancy is uncommon." | 1.42 | Chemotherapeutic treatment of colorectal cancer in pregnancy: case report. ( Al-Khatani, K; Al-Mohaisen, F; Makoshi, Z; Perrott, C, 2015) |
| "Patients newly diagnosed with ovarian cancer between 1997 and 2010 were identified using Taiwan's National Health Insurance database." | 1.42 | Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study. ( Chao, Y; Chen, MH; Chen, TJ; Chiou, TJ; Hu, YW; Hung, YP; Li, CP; Liu, CJ; Yang, MH; Yeh, CM, 2015) |
| "She underwent curative resection for sigmoid colon cancer( T4a, N2, M0, Stage IIIC)." | 1.39 | [Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer]. ( Baba, H; Iida, S; Ishiguro, M; Ishikawa, T; Iwata, N; Kikuchi, A; Kobayashi, H; Okazaki, S; Sugihara, K; Takahashi, H; Uetake, H, 2013) |
| "Median age at gastric cancer diagnosis was 48." | 1.39 | Chemosensitivity in ovarian metastases from gastric cancer: a case series. ( Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A, 2013) |
| "Clinicopathological data of 257 cM1 gastric cancer patients who underwent an operation at Seoul National University Hospital from January 1999 to December 2004 were reviewed." | 1.38 | The value of palliative gastrectomy in gastric cancer with distant metastasis. ( Chang, YR; Han, DS; Kim, SH; Kim, WH; Kong, SH; Lee, HJ; Yang, HK, 2012) |
| "Elafin has been reported to be abundantly expressed in human epithelial ovarian carcinoma (EOC), however, its functions are poorly understood." | 1.38 | Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. ( Hellström, I; Hellström, KE; Wei, H, 2012) |
| "We found a 2." | 1.38 | Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk. ( Bao, L; Hao, Q; Liu, W; Wang, K; Zhang, L, 2012) |
| "A detailed examination revealed a rectal cancer with metastasis to the right ovary." | 1.37 | [A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy]. ( Hatakeyama, K; Iiai, T; Kameyama, H; Nogami, H; Saitou, K; Umezu, H; Yagi, Y, 2011) |
| "It inhibits the intracellular enzyme in ovarian cancer cells and reduces cellular growth at low micromolar concentrations in both cisplatin-sensitive and -resistant cells without causing protein overexpression." | 1.37 | Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. ( Cardinale, D; Costi, MP; Ferrari, S; Fessas, D; Frassineti, C; Guaitoli, G; Guerrieri, D; Guerrini, R; Henrich, S; Ligabue, A; Luciani, R; Mangani, S; Marverti, G; Ponterini, G; Pozzi, C; Salo-Ahen, OM; Tondi, D; Wade, RC, 2011) |
| "Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells." | 1.37 | Novel activity of acriflavine against colorectal cancer tumor cells. ( Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L, 2011) |
| "The siRNA was transfected into human ovarian cancer cell line OVCAR8/TR by liposome." | 1.35 | [Improve the chemosensitivity of resistant ovarian cancer cell by small RNA interference]. ( He, B; Lou, JY; Peng, ZL; Zheng, Y, 2008) |
| "The most common malignancy is squamous cell carcinoma, which consists of about 75% of malignant transformations." | 1.35 | Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report. ( Azadbakht, F; Emami-Aleagha, M; Hajarizadeh, B; Keshvari, A; Rosai, J; Sedighi, S; Shariat-Torbaghan, S, 2009) |
| "Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)." | 1.35 | Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. ( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008) |
| "Gastrointestinal perforations were identified in 9%." | 1.33 | Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. ( Gibb, RK; Hagemann, A; Mutch, DG; Norris, L; Powell, MA; Rader, JS; Viviano, D; Wright, JD, 2006) |
| "Type IV advanced gastric cancer was diagnosed on upper gastrointestinal endoscopy." | 1.33 | [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor]. ( Higuchi, K; Kobayashi, N; Koizumi, W; Mitomi, H; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S, 2006) |
| " Finally, examination of nitroreductase/CB1954 in combination with conventional chemotherapy reveals a synergistic interaction with 5-fluorouracil." | 1.32 | Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. ( Kerr, DJ; Milner, AE; Palmer, DH; Young, LS, 2003) |
| "Irofulven has demonstrated potent activity against a broad range of solid tumors in both cellular and xenograft models and has shown promising activity in clinical trials." | 1.32 | Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. ( Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ, 2003) |
| "A 59-year-old woman with advanced ovarian cancer complained of massive refractory ascites after 2 years' history of chemotherapy." | 1.32 | [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion]. ( Fujimoto, S; Kobayashi, K; Mutou, T; Ogasawara, T; Ohtsuka, Y; Takahashi, M; Toyosawa, T, 2003) |
| "Case 1 A 40-year-old female with gastric cancer located in the MULE area underwent total gastrectomy with D3 lymph node dissection on June 2, 1989." | 1.32 | [Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection]. ( Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T, 2003) |
| " The parameters of the pharmacodynamic model are related to the growth characteristics of the tumor, to the drug potency, and to the kinetics of the tumor cell death." | 1.32 | Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. ( Cammia, C; Croci, V; De Nicolao, G; Germani, M; Magni, P; Pesenti, E; Poggesi, I; Rocchetti, M; Simeoni, M, 2004) |
| "Verapamil treatment did not reverse the intrinsic drug resistance of parental cells, but partially modulated the sensitivity of CABA-PTX cells to PTX and induced total sensitivity to vinblastine." | 1.32 | Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line. ( Canevari, S; D'Ascenzo, S; Dolo, V; Millimaggi, D; Miotti, S; Pavan, A; Violini, S, 2004) |
| "As a model two different human ovary cancer cell lines were used." | 1.32 | Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations. ( Huober, J; Mueck, AO; Seeger, H; Wallwiener, D, 2004) |
| "Higher TP expression was observed in ovarian cancers than in normal ovaries." | 1.32 | [Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer]. ( Akimoto, T; Hasegawa, K; Kishimoto, Y; Morimoto, Y; Sawai, T, 2004) |
| "Ovarian metastasis is frequent." | 1.31 | Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. ( Blanchot, J; Boucher, E; Corbinais, S; Garin, L; Le Guilcher, P; Raoul, JL, 2002) |
| "The oestrogen receptor positive breast cancer cell lines (MCF-7, T47D) demonstrated an increased level of HSP 27 and 70 expression compared with oestrogen receptor negative cell lines (BT20, HBL100)." | 1.31 | Heat shock protein expression in human tumours grown in severe combined immunodeficient mice. ( Katoh, M; Koninkx, J; Schumacher, U, 2000) |
| "Paclitaxel was more effective in clear cells than serous papillary cells." | 1.31 | Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. ( Gorai, I; Hirahara, F; Kawata, N; Miyamoto, Y; Ohta, I; Shirotake, S; Yang, J; Zheng, JH, 2001) |
| "The Ovcar-5 and Skov-3 ovarian cancer cell lines exposed to the Ad-Lp-CD adenoviral vector were much more sensitive to the prodrug 5-fluorocytosine (5FC), which is converted from the 5FC prodrug into the toxic chemical 5-fluorouracil, than was the CCD minimal deviation fibroblast cell line after exposure to the same vector." | 1.31 | The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. ( Crystal, R; Deisseroth, A; Fujii, T; Kacinski, B; Leavitt, J; Peng, XY; Pizzorno, G; Rutherford, T; Sapi, E; Schwartz, P; Won, JH; Zelterman, D, 2001) |
| "A clinically important myelosuppression due to adjuvant chemotherapy is seen more frequently as dosage is intensified and new drugs are used." | 1.31 | [Chemotherapy-associated myelosuppression in gynecological oncology]. ( Bergauer, F; Dimpfl, T; Janni, W; Kaestner, R; Linka, F; Rack, B; Rjosk, D; Schindlbeck, C; Sommer, H; Strobl, B, 2001) |
| "What roles TK may play in epithelial ovarian cancer and the relationships between TK and the other pyrimidine pathway enzymes remain unclear." | 1.31 | Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes. ( Fujiwaki, R; Hata, K; Iwanari, O; Katabuchi, H; Miyazaki, K; Moriyama, M; Nakayama, K; Okamura, H; Sakai, E, 2002) |
| " In order to assess the mode of action of lobaplatin when combined with 5-FU, two human cancer cell lines were treated with various combinations of 5-FU given for either 2 or 24h and lobaplatin." | 1.30 | Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines. ( Druyen, H; Harstrick, A; Heidemann, A; Seeber, S; Vanhoefer, U; Wilke, H, 1997) |
| " This study investigates the cytotoxic effects of oxaliplatin in combination with 5-FU and AG337 in cultured human colon (HT29, CaCo2), breast (MCF-7, MDA-MB-231) and ovarian (2008) cancer cell lines, and their derived counterparts selected for their resistance to 5-FU (HT29-5-FU), doxorubicin (MCF-7mdr) or cisplatin (2008C13)." | 1.30 | Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. ( Allain, P; Buquet-Fagot, C; Cvitkovic, E; Djelloul, S; Gespach, C; Louvet, C; Mester, J; Raymond, E, 1997) |
| "Titanium-DNA adducts were detected in A2780 cells treated with titanocene dichloride using atomic absorption spectrometry, suggesting that DNA may be a target for this drug." | 1.30 | Anti-proliferative activity and mechanism of action of titanocene dichloride. ( Christodoulou, CV; Eliopoulos, AG; Ferry, DR; Hodgkins, L; Kerr, DJ; Young, LS, 1998) |
| "Fluorouracil (5-FU) was repeatedly injected into the pelvic retroperitoneal space of 43 patients and the abdominal cavity of 11 patients." | 1.30 | [The contrast between chemotherapy via pelvic retroperitoneal cannulation and intraperitoneal chemotherapy in gynecological malignancies cancers with lymph node metastases]. ( Cao, Z; Peng, Z; Zhang, D, 1999) |
| " We also studied the combined antitumor potential of rhTNF with the five chemotherapeutic agents and the results showed that there were various degrees of synergism in cytotoxicities of rhTNF in combination with DDP or KSM on the two cell lines." | 1.29 | Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice. ( Fu, C; Lian, L; Shen, B; Zhang, Q; Zhao, E; Zhou, M, 1995) |
| "A group of 298 patients with epithelial ovarian cancer were treated with combination chemotherapy between July 1979 and January 1986 at the Tokai Ovarian Tumor Study Group." | 1.29 | Long-term follow-up of patients with epithelial carcinoma of the ovary. ( Arii, Y; Hattori, S; Kawai, M; Kikkawa, F; Ohta, M; Tomoda, Y, 1994) |
| "Melphalan (MEL) was the only drug used in single-drug chemotherapy." | 1.29 | Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. ( Friberg, LG; Granberg, S; Islam, MQ; Köpf, I; Levan, A; Levan, G, 1993) |
| "Radically excised ovarian cancers present an unsolved problem with regard to the value of routine second-look operation." | 1.29 | Second-look laparotomy in the management of patients after radical surgery for ovarian cancer. ( Hansen, M; Hansen, OP; Lund, B; Tuxen, MK, 1993) |
| "Epirubicin and TNF-alpha were the two major cytotoxic agents to NIH: OVCAR-3." | 1.29 | [Synergistic effects of tumor necrosis factor interferon-gamma and chemotherapeutic drugs on human ovarian cancer cell lines in vitro]. ( Hui, N; Li, J; Zhu, L, 1995) |
| "pDOR-erbB-neo was introduced into human ovarian cancer cell line SKOV3 by lipofectin." | 1.29 | [Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells]. ( Jiang, K; Wu, A; Wu, L, 1996) |
| "Seven consecutive advanced ovarian cancer patients presented with massive ascites (5 with pleural effusion)." | 1.28 | [Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations]. ( Fujimoto, I; Hasumi, K; Masubuchi, K; Shimizu, Y; Tatsuki, Y; Yamauchi, K, 1992) |
| "Fourteen patients with relapsing ovarian cancer were treated with Mitomycin C (Mit C) and 5 Fluorouracil (5-FU)." | 1.28 | Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer. ( Covens, A; Mazurka, J; O'Connell, G; Rusthoven, J, 1992) |
| "In uterine cervical cancer, each group of 9 cases administered single dose of 400 mg of 5'-DFUR and 7 cases administered 400 mg of 5'-DFUR 3 times a day continuously for 7 days was investigated." | 1.28 | [Investigation of 5-fluorouracil (5-FU) levels and pyrimidine nucleoside phosphorylase activities in the tissues from patients with uterine cervical and ovarian cancers after oral administration of 5'-DFUR]. ( Hasegawa, K; Ikeda, M; Kinugasa, M; Kobashi, Y; Noda, K; Odagiri, H; Ohiwa, T; Sekiba, K; Takeuchi, K; Watanabe, Y, 1991) |
| " Single-agent and combined dose-response patterns consisting of decreasing viability with increasing drug concentration were observed consistently." | 1.28 | Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. ( Averette, HE; Gerhardt, RT; Guerra, L; Perras, JP; Petru, E; Ramos, R; Sevin, BU, 1991) |
| "Nephrotoxicity is the major side effect of cisplatinum (CDDP) and it is often the dose limiting factor." | 1.28 | [Effects of urinastatin against nephrotoxicity of cisplatinum]. ( Arakawa, A; Asai, H; Kato, N; Suzumori, K; Yagami, Y; Yasui, Y, 1990) |
| "Fifty-two patients with ovarian cancer (post surgical residual tumor) were treated with the combination of platinum + epirubicin (PE) (P 50mg/m2, E 60 mg/m2) alternated with cyclophosphamide + 5-fluorouracil (CF) (C 800 mg/m2, F 600 mg/m2)." | 1.28 | Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer. ( Bellucco, A; Canova, N; Ercolino, L; Lelli, G; Martoni, A; Pannuti, F, 1990) |
| "Fourteen samples of epithelial ovarian cancer were studied; chemosensitivity in vitro was examined by clonogenic assay, and DNA content was measured by static cytometry." | 1.28 | Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results. ( Carenza, L; Giovagnoli, MR; Prosperi Porta, R; Rulli, G, 1990) |
| " For each drug in each cell line, a highly reproducible dose-response relationship was observed." | 1.28 | Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. ( Averette, HE; Boike, G; Nguyen, H; Perras, J; Petru, E; Ramos, R; Sevin, BU, 1990) |
| "Two human ovarian cancer cell lines were established from a patient before (PEO1) and after (PEO4) the onset of resistance to 5-fluorouracil (5-FU)/cisplatin-based chemotherapy." | 1.28 | Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. ( Allegra, CJ; Chu, E; Lai, GM; Zinn, S, 1990) |
| "A patient with ovarian cancer recurrent in the pelvis showed partial response to consecutive intraarterial (IA) cisplatin (CDDP) combined with continuous IA 5FU treatment and received third look operation in which the recurrent tumor could not be completely removed." | 1.28 | [Successful treatment of a patient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU]. ( Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Masubuchi, K; Nakayama, K; Shimizu, Y; Teshima, H; Yamauchi, K, 1989) |
| " Other adverse sequelae, such as abdominal pain, were manageable with medication." | 1.28 | Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study. ( Blessing, JA; Homesley, HD; Walton, LA, 1989) |
| "Of 89 samples of cancer cells from ovarian cancer patients primary cultures representative of the cancer cell population could be established in 17." | 1.27 | Clinical correlates of in vitro drug sensitivities of ovarian cancer cells. ( Erba, E; Garattini, S; Ghelardoni, C; Landoni, F; Mangioni, C; Morasca, L; Sessa, C; Vaghi, M, 1983) |
| " It is likely that the reduced drug dosage might have contributed to the poor clinical response." | 1.27 | Timed sequential chemotherapy following drug-induced kinetic recruitment in refractory ovarian cancer. ( Alama, A; Conte, PF; Favoni, R; Nicolin, A; Rosso, R; Trave, F, 1984) |
| "Melphalan (L-PAM) was compared to (C) cyclophosphamide, (M) methotrexate, and (F) 5-fluorouracil (CMF) in 413 patients with advanced ovarian carcinoma." | 1.27 | Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. ( Bauer, M; Brodovsky, HS; Elson, PJ; Horton, J, 1984) |
| " HCFU might be effective against gynecologic cancers when used in maintenance therapy at a lower dosage (300--400 mg) than previously estimated." | 1.27 | Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue. ( Matsui, Y; Okudaira, Y; Sawada, M, 1983) |
| "Twenty-seven patients with advanced ovarian cancer were treated with CAPF therapy consisting of CPA, ADM, CPDD, and 5-FU." | 1.27 | [Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation]. ( Aiba, K; Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Komyo, M; Kubo, H; Miyamoto, H; Ogawa, M, 1983) |
| "Individual ovarian cancers showed different sensitivities to the drugs." | 1.27 | [A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect]. ( Ishige, H; Iwasawa, H; Sekiya, S; Takamizawa, H; Tanaka, N; Tokita, H, 1985) |
| "A metastatic renal cell carcinoma was found on the pelvic peritoneum and characteristic renal cancer cells were identified in the ascitic fluid." | 1.27 | [Synchronous double cancers in the ovary and kidney--a case report]. ( Fujiwara, A; Katsube, Y; Myoga, H; Nogawa, T; Ohta, S; Shigemasa, K; Shinko, Y; Tamaki, M, 1988) |
| "A case of brain metastasis in ovarian cancer is reported." | 1.27 | [Metastatic brain tumor after chemotherapy of ovarian cancer]. ( Chen, JT; Fujimoto, I; Fukuda, K; Hasumi, K; Masubuchi, K; Sakamoto, A; Yamauchi, K, 1987) |
| "Dimethyl sulfoxide is a well-known differentiating agent that has been shown to inhibit tumor growth in vitro." | 1.27 | Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro. ( Fletcher, WS; Milo, G; Pommier, RF; Woltering, EA, 1988) |
| "Furthermore, the 5-FU level in ovarian cancer tissues was much higher than that in the tissues of the contralateral normal ovary, suggesting that degradation of 5-FU might be delayed in cancer tissue." | 1.27 | [Estimation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5-FU concentrations in sera and resected specimens from patients with ovarian tumors]. ( Iguchi, T; Ino, Y; Isono, T; Sato, M; Takeda, Y; Takizawa, K; Yokoo, I, 1988) |
| " Even so, HCFU should be dosed when needed in spite of this risk." | 1.27 | [A case of leukoencephalopathy caused by HCFU]. ( Abe, S; Kamata, H; Kisida, S; Miyagawa, N; Murakami, A; Nagano, H; Ueda, K; Yasui, H, 1988) |
| "Dysgerminomas are highly sensitive not only to irradiation but also to chemotherapy." | 1.27 | [Chemotherapy of dysgerminoma]. ( Brökelmann, J; Hartlapp, JH, 1987) |
| "The prognosis of ovarian cancer remains extremely poor since 19 patients died, 6 were lost to follow-up and considered as dead, and out of 5 living patients after 10 months, only 2 were in complete remission." | 1.27 | [Primary cancer of the ovary: anatomoclinical varieties and therapeutic problems in Brazzaville]. ( Cardorelle, A; Gombe-M'balawa, CH; N'Koua-M'Bon, JB; Paraiso, ID, 1987) |
| " Drug dose-response and time-response curves were plotted, and the IC50 ratio was calculated, for each test compound in order to investigate the mechanism of anticancer action." | 1.27 | [In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents]. ( Fujiya, S; Hatiya, S; Nakabayashi, Y; Tahira, K; Terashima, Y; Yasuda, M; Yoshioka, M, 1985) |
| "Treatment of patients with advanced ovarian cancer who have failure of first-line chemotherapy is rarely effective." | 1.27 | Intraperitoneal chemotherapy for advanced ovarian cancer. ( Howell, SB; Lucas, WE; Markman, M, 1985) |
| " The group of long term administration of FT-207 and CQ included many patients with good response." | 1.26 | [Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer]. ( Fukuda, O; Inoue, S; Maeyama, M; Nakayama, M; Tajima, C; Tokunaga, T, 1982) |
| " The results are discussed in relation to the pharmacokinetic availability of drugs in the plasma compartment of patients treated by different therapuetic regimens." | 1.26 | Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity. ( Balconi, G; D'Incalci, M; Erba, E; Garattini, S; Morasca, L; Ottolenghi, L; Salmona, A, 1980) |
| "Successful heterotransplantation of ovarian cancer in the mouse mutant, nude is described, with serial transmission, in one case to date." | 1.26 | Heterologous growth of human ovarian cancer. A new in vivo testing system. ( Davy, M; Johannessen, JV; Mossige, J, 1977) |
| "Thirteen cases of acute nonlymphocytic leukemia occurred among 5455 patients, as compared to 0." | 1.26 | Acute leukemia after alkylating-agent therapy of ovarian cancer. ( Fraumeni, JF; Hoover, R; Reimer, RR; Young, RC, 1977) |
| "Two patients with generalized ovarian cancer may be cured." | 1.26 | Chemotherapy of ovarian cancer. ( Dimitriades, M; Midoulas, N; Panopoulos, C; Papadimitriou, GC; Razis, DV, 1978) |
| "A series of 25 patients with malignant teratoma of the ovary is presented." | 1.26 | Malignant teratoma of the ovary: prognostic factors and treatment. ( Curry, SL; Gallagher, HS; Smith, JP, 1978) |
| "The treatment of breast and ovarian cancer brought the best results, improved by a synchronisation therapy." | 1.26 | [Five years treatment of advanced solid malignomas with a combination of four cytostatic drugs (author's transl)]. ( Siebner, H; Weber, W, 1976) |
| "The topography of the neoplasm had no influence on the I." | 1.25 | Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors. ( Dubois, JB; Serrou, B, 1975) |
| "All 14 patients with breast carcinoma underwent remission and in 6 this was complete." | 1.25 | Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime. ( Hanham, IW; Newton, KA; Westbury, G, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 264 (52.28) | 18.7374 |
| 1990's | 103 (20.40) | 18.2507 |
| 2000's | 71 (14.06) | 29.6817 |
| 2010's | 58 (11.49) | 24.3611 |
| 2020's | 9 (1.78) | 2.80 |
| Authors | Studies |
|---|---|
| Carosati, E | 3 |
| Tochowicz, A | 1 |
| Marverti, G | 10 |
| Guaitoli, G | 2 |
| Benedetti, P | 1 |
| Ferrari, S | 9 |
| Stroud, RM | 3 |
| Finer-Moore, J | 1 |
| Luciani, R | 7 |
| Farina, D | 1 |
| Cruciani, G | 3 |
| Costi, MP | 10 |
| Riganas, S | 1 |
| Papanastasiou, I | 1 |
| Foscolos, GB | 1 |
| Tsotinis, A | 1 |
| Serin, G | 1 |
| Mirjolet, JF | 1 |
| Dimas, K | 1 |
| Kourafalos, VN | 1 |
| Eleutheriades, A | 1 |
| Moutsos, VI | 1 |
| Khan, H | 1 |
| Georgakopoulou, S | 1 |
| Zaniou, A | 1 |
| Prassa, M | 1 |
| Theodoropoulou, M | 1 |
| Mantelas, A | 1 |
| Pondiki, S | 1 |
| Vamvakides, A | 1 |
| Pelà, M | 2 |
| Saxena, P | 4 |
| Santucci, M | 5 |
| Marraccini, C | 4 |
| Martello, A | 2 |
| Pirondi, S | 2 |
| Genovese, F | 3 |
| Salvadori, S | 1 |
| D'Arca, D | 6 |
| Ponterini, G | 8 |
| Guerrini, R | 7 |
| Cannazza, G | 4 |
| Cazzato, AS | 2 |
| Pavesi, G | 1 |
| Frassineti, C | 3 |
| Severi, L | 2 |
| Taddia, L | 1 |
| Tondi, D | 2 |
| Mor, M | 1 |
| Scalvini, L | 1 |
| Vitiello, S | 1 |
| Losi, L | 5 |
| Fonda, S | 1 |
| Pacifico, S | 5 |
| Spyrakis, F | 1 |
| Gozzi, G | 4 |
| Lauriola, A | 4 |
| Tagliazucchi, L | 3 |
| Costantino, L | 2 |
| Salo-Ahen, OMH | 2 |
| Franchini, S | 2 |
| Pozzi, C | 3 |
| Trande, M | 2 |
| Cardinale, D | 3 |
| Venturelli, A | 2 |
| Quotadamo, A | 2 |
| Linciano, P | 2 |
| Moschella, MG | 2 |
| Henrich, S | 3 |
| Alboni, S | 2 |
| Santarem, N | 2 |
| da Silva Cordeiro, A | 2 |
| Giovannetti, E | 2 |
| Peters, GJ | 2 |
| Pinton, P | 2 |
| Rimessi, A | 2 |
| Wade, RC | 3 |
| Mangani, S | 3 |
| Li, G | 1 |
| Nikkhoi, SK | 1 |
| Hatefi, A | 1 |
| Schcolnik-Cabrera, A | 1 |
| Juárez, M | 1 |
| Oldak, B | 1 |
| Cruz-Rivera, M | 1 |
| Flisser, A | 1 |
| Dueñas-González, A | 1 |
| Buzoianu-Anguiano, V | 1 |
| Orozco-Suarez, S | 1 |
| Mendlovic, F | 1 |
| Tanabe, Y | 1 |
| Shiraishi, S | 1 |
| Hashimoto, K | 1 |
| Ikeda, K | 2 |
| Nishizawa, D | 1 |
| Hasegawa, J | 1 |
| Shimomura, A | 1 |
| Ozaki, Y | 1 |
| Tamura, N | 1 |
| Yunokawa, M | 1 |
| Yonemori, K | 1 |
| Takano, T | 1 |
| Kawabata, H | 1 |
| Tamura, K | 1 |
| Fujiwara, Y | 1 |
| Shimizu, C | 1 |
| Li, H | 1 |
| Zhou, Y | 1 |
| Cheng, H | 1 |
| Tian, J | 1 |
| Yang, S | 1 |
| Maretti, E | 1 |
| Sacchetti, F | 1 |
| Leo, E | 1 |
| Qu, H | 1 |
| Xia, Y | 1 |
| Li, X | 2 |
| Ben Nasr, S | 1 |
| Zribi, A | 1 |
| Ben Hassen, M | 1 |
| Doghri, Y | 1 |
| Ben Abdallah, I | 1 |
| Trigui, E | 1 |
| Fendri, S | 1 |
| Ayari, J | 1 |
| Balti, M | 1 |
| Haddaoui, A | 1 |
| Ling, C | 1 |
| Liu, S | 3 |
| Wang, Y | 3 |
| Zhang, FC | 1 |
| DU, Y | 1 |
| Bruckner, HW | 3 |
| Gurell, D | 1 |
| Hirschfeld, A | 1 |
| Li, N | 1 |
| Lin, Z | 1 |
| Chen, W | 1 |
| Zheng, Y | 2 |
| Ming, Y | 1 |
| Zheng, Z | 1 |
| Huang, W | 1 |
| Chen, L | 1 |
| Xiao, J | 1 |
| Lin, H | 1 |
| Fernández, LP | 1 |
| Sánchez-Martínez, R | 1 |
| Vargas, T | 1 |
| Herranz, J | 1 |
| Martín-Hernández, R | 1 |
| Mendiola, M | 1 |
| Hardisson, D | 1 |
| Reglero, G | 1 |
| Feliu, J | 1 |
| Redondo, A | 1 |
| Ramírez de Molina, A | 1 |
| Huang, C | 1 |
| Clayton, EA | 1 |
| Matyunina, LV | 1 |
| McDonald, LD | 1 |
| Benigno, BB | 1 |
| Vannberg, F | 1 |
| McDonald, JF | 1 |
| Hu, ZI | 1 |
| Hellmann, MD | 1 |
| Wolchok, JD | 1 |
| Vyas, M | 1 |
| Shia, J | 1 |
| Stadler, ZK | 1 |
| Diaz, LA | 1 |
| O'Reilly, EM | 1 |
| Bormio Nunes, JH | 1 |
| de Paiva, PP | 1 |
| Ruiz, ALTG | 1 |
| de Carvalho, JE | 1 |
| Corbi, PP | 1 |
| Horvath, P | 1 |
| Beckert, S | 1 |
| Königsrainer, A | 1 |
| Nadalin, S | 1 |
| Königsrainer, I | 1 |
| Burgazli, KM | 1 |
| Mericliler, M | 1 |
| Kavukcu, E | 1 |
| Erdogan, A | 1 |
| Ertan, AK | 1 |
| Oranratanaphan, S | 1 |
| Khemapech, N | 1 |
| Kohorn, EI | 1 |
| Kobayashi, H | 1 |
| Uetake, H | 1 |
| Iida, S | 1 |
| Ishikawa, T | 1 |
| Ishiguro, M | 1 |
| Okazaki, S | 1 |
| Kikuchi, A | 1 |
| Baba, H | 1 |
| Takahashi, H | 2 |
| Iwata, N | 1 |
| Sugihara, K | 1 |
| Xu, X | 2 |
| Dai, H | 1 |
| Zhao, Y | 1 |
| Qian, Z | 1 |
| Chen, X | 1 |
| Chen, J | 2 |
| Wang, J | 1 |
| Zhang, Y | 3 |
| Chen, D | 1 |
| Yang, C | 1 |
| Kai, C | 1 |
| Wang, X | 3 |
| Shi, F | 1 |
| Dou, J | 1 |
| Saczko, J | 1 |
| Kamińska, I | 1 |
| Kotulska, M | 1 |
| Bar, J | 1 |
| Choromańska, A | 1 |
| Rembiałkowska, N | 1 |
| Bieżuńska-Kusiak, K | 1 |
| Rossowska, J | 1 |
| Nowakowska, D | 1 |
| Kulbacka, J | 1 |
| Yamaguchi, T | 2 |
| Kurita, T | 1 |
| Nishio, K | 1 |
| Tsukada, J | 1 |
| Hachisuga, T | 1 |
| Morimoto, Y | 2 |
| Iwai, Y | 1 |
| Izumi, H | 1 |
| Wang, YJ | 1 |
| Liu, JB | 1 |
| Dou, YC | 1 |
| Deme, D | 1 |
| Bishr, AM | 1 |
| Nizar, J | 1 |
| Telekes, A | 1 |
| Zhang, H | 1 |
| Jing, X | 1 |
| Wu, X | 1 |
| Hu, J | 1 |
| Zhang, X | 1 |
| Su, P | 1 |
| Li, W | 1 |
| Zhou, G | 1 |
| Makoshi, Z | 1 |
| Perrott, C | 1 |
| Al-Khatani, K | 1 |
| Al-Mohaisen, F | 1 |
| Bibeau, F | 1 |
| Dartigues, P | 2 |
| Hung, YP | 1 |
| Liu, CJ | 1 |
| Hu, YW | 1 |
| Chen, MH | 1 |
| Li, CP | 1 |
| Yeh, CM | 1 |
| Chiou, TJ | 1 |
| Chen, TJ | 1 |
| Yang, MH | 1 |
| Chao, Y | 1 |
| Brieau, B | 2 |
| Auzolle, C | 1 |
| Pozet, A | 1 |
| Tougeron, D | 1 |
| Bouché, O | 1 |
| Soibinet, P | 1 |
| Coriat, R | 1 |
| Prieux, C | 1 |
| Lecomte, T | 1 |
| Goujon, G | 1 |
| Marthey, L | 1 |
| Rougier, P | 2 |
| Bonnetain, F | 1 |
| Ducreux, M | 1 |
| Taieb, J | 2 |
| Zaanan, A | 2 |
| Huang, KC | 1 |
| Yang, J | 3 |
| Ng, MC | 1 |
| Ng, SK | 1 |
| Welch, WR | 1 |
| Muto, MG | 1 |
| Berkowitz, RS | 1 |
| Ng, SW | 1 |
| Bai, H | 1 |
| Cao, D | 1 |
| Yuan, F | 1 |
| Sha, G | 1 |
| Zhang, Z | 1 |
| Shen, K | 1 |
| Baehr, CA | 1 |
| Huntoon, CJ | 2 |
| Hoang, SM | 1 |
| Jerde, CR | 1 |
| Karnitz, LM | 2 |
| Akiyama, M | 1 |
| Sowa, Y | 1 |
| Taniguchi, T | 1 |
| Watanabe, M | 1 |
| Yogosawa, S | 1 |
| Kitawaki, J | 1 |
| Sakai, T | 1 |
| Ohara, N | 1 |
| Haraguchi, N | 1 |
| Kudo, T | 1 |
| Nishimura, J | 1 |
| Hata, T | 2 |
| Matsuda, C | 1 |
| Satoh, T | 1 |
| Mizushima, T | 1 |
| Yamamoto, H | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Lou, JY | 1 |
| Peng, ZL | 2 |
| He, B | 2 |
| He, Z | 1 |
| Gao, J | 1 |
| Wang, Q | 1 |
| Liu, M | 1 |
| Li, Y | 1 |
| Tang, H | 1 |
| Zheng, J | 1 |
| Watari, H | 1 |
| Hosaka, M | 1 |
| Mitamura, T | 1 |
| Moriwaki, M | 1 |
| Ohba, Y | 1 |
| Todo, Y | 1 |
| Takeda, M | 1 |
| Ebina, Y | 1 |
| Sakuragi, N | 1 |
| Sato, S | 3 |
| Itamochi, H | 1 |
| Kigawa, J | 1 |
| Oishi, T | 1 |
| Shimada, M | 1 |
| Naniwa, J | 1 |
| Uegaki, K | 1 |
| Nonaka, M | 1 |
| Terakawa, N | 1 |
| Shariat-Torbaghan, S | 1 |
| Emami-Aleagha, M | 1 |
| Sedighi, S | 1 |
| Azadbakht, F | 1 |
| Keshvari, A | 1 |
| Hajarizadeh, B | 1 |
| Rosai, J | 1 |
| Pisano, C | 1 |
| Morabito, A | 1 |
| Sorio, R | 1 |
| Breda, E | 1 |
| Lauria, R | 1 |
| Gebbia, V | 1 |
| Scaltriti, L | 1 |
| Scalone, S | 1 |
| Zagonel, V | 1 |
| Greggi, S | 2 |
| Beneduce, G | 1 |
| Losito, S | 1 |
| Gallo, C | 1 |
| Di Maio, M | 1 |
| Forestieri, V | 1 |
| Pignata, S | 1 |
| Dubois, N | 1 |
| Willems, T | 1 |
| Myant, N | 1 |
| Markman, M | 7 |
| Brady, M | 1 |
| Hutson, A | 1 |
| Berek, JS | 2 |
| Ligabue, A | 2 |
| Paglietti, G | 1 |
| Corona, P | 1 |
| Piras, S | 1 |
| Vitale, G | 1 |
| Guerrieri, D | 2 |
| Moruzzi, MS | 1 |
| Safra, T | 1 |
| Bernstein Molho, R | 1 |
| Menzcher, J | 1 |
| Inbar, M | 1 |
| Grisaru, D | 1 |
| Levy, T | 1 |
| Shindo, Y | 1 |
| Tenma, K | 1 |
| Okuyama, M | 1 |
| Hibino, M | 1 |
| Sasaki, Y | 1 |
| Kitamura, T | 1 |
| Nakamura, M | 3 |
| Nagy, Z | 1 |
| Turcsik, V | 1 |
| Blaskó, G | 1 |
| Kadikoylu, G | 1 |
| Barutca, S | 1 |
| Tataroglu, C | 1 |
| Kafkas, S | 1 |
| Erpek, H | 1 |
| Meydan, N | 1 |
| Yavasoglu, I | 1 |
| Bolaman, Z | 1 |
| Nishimura, T | 1 |
| Maeda, Y | 1 |
| Okada, T | 1 |
| Sakata, K | 1 |
| Setoguchi, M | 1 |
| Kawasaki, N | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Fedyanin, MY | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 1 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 1 |
| Tjulandin, SA | 1 |
| Sholi, A | 1 |
| Martino, MA | 1 |
| Martino, MM | 1 |
| Pirigyi, M | 1 |
| Rosenblum, NG | 1 |
| Peterson, CS | 1 |
| Bradbury, AR | 1 |
| Morris, GJ | 1 |
| Husein-ElAhmed, H | 1 |
| Aneiros-Fernandez, J | 1 |
| Arias-Santiago, S | 1 |
| Naranjo-Sintes, R | 1 |
| Kwon, HC | 1 |
| Kim, MC | 1 |
| Kim, KH | 1 |
| Jang, JS | 1 |
| Oh, SY | 1 |
| Kim, SH | 2 |
| Kwon, KA | 1 |
| Lee, S | 1 |
| Lee, HS | 1 |
| Kim, HJ | 1 |
| Yang, XY | 1 |
| Yu, H | 1 |
| Camacho, LH | 1 |
| Garcia, S | 1 |
| Panchal, AM | 1 |
| Lim, J | 1 |
| Hong, DS | 1 |
| Ng, C | 1 |
| Madoff, DC | 1 |
| Fu, S | 1 |
| Gayed, I | 1 |
| Kurzrock, R | 1 |
| Okubo, K | 1 |
| Yoshioka, S | 1 |
| Asukai, K | 1 |
| Nakanishi, M | 1 |
| Maekawa, T | 1 |
| Hama, N | 1 |
| Kashiwazaki, M | 1 |
| Taniguchi, M | 1 |
| Tsujie, M | 1 |
| Konishi, M | 1 |
| Yano, K | 1 |
| Fujimoto, T | 1 |
| Kim, ST | 1 |
| Choi, YJ | 2 |
| Park, KH | 1 |
| Oh, SC | 1 |
| Seo, JH | 1 |
| Shin, SW | 1 |
| Kim, JS | 1 |
| Kim, YH | 1 |
| Zhao, WY | 1 |
| Chen, DY | 1 |
| Qi, Q | 1 |
| Schott, S | 1 |
| Wallwiener, M | 1 |
| Kootz, B | 1 |
| Seeger, H | 2 |
| Fehm, T | 1 |
| Neubauer, H | 1 |
| Huehls, AM | 1 |
| Wagner, JM | 1 |
| Geng, L | 1 |
| Erlichman, C | 2 |
| Patel, AG | 1 |
| Kaufmann, SH | 1 |
| Yagi, Y | 1 |
| Iiai, T | 1 |
| Saitou, K | 2 |
| Kameyama, H | 1 |
| Nogami, H | 1 |
| Umezu, H | 1 |
| Hatakeyama, K | 1 |
| Salo-Ahen, OM | 1 |
| Fessas, D | 1 |
| Hassan, S | 1 |
| Laryea, D | 1 |
| Mahteme, H | 1 |
| Felth, J | 1 |
| Fryknäs, M | 1 |
| Fayad, W | 1 |
| Linder, S | 1 |
| Rickardson, L | 1 |
| Gullbo, J | 1 |
| Graf, W | 1 |
| Påhlman, L | 1 |
| Glimelius, B | 1 |
| Larsson, R | 1 |
| Nygren, P | 1 |
| Honda, K | 1 |
| Hata, Y | 1 |
| Ihara, E | 1 |
| Tomita, Y | 1 |
| Miyata, S | 1 |
| Sumida, Y | 1 |
| Ihara, Y | 1 |
| Misawa, T | 1 |
| Chang, YR | 1 |
| Han, DS | 1 |
| Kong, SH | 1 |
| Lee, HJ | 1 |
| Kim, WH | 1 |
| Yang, HK | 1 |
| Wei, H | 1 |
| Hellström, KE | 1 |
| Hellström, I | 1 |
| Kim, KK | 1 |
| Lange, TS | 1 |
| Singh, RK | 1 |
| Brard, L | 1 |
| Moore, RG | 1 |
| Zhang, L | 1 |
| Liu, W | 1 |
| Hao, Q | 1 |
| Bao, L | 1 |
| Wang, K | 1 |
| Tanaka, K | 2 |
| Hirai, K | 1 |
| Ogawa, H | 2 |
| Toya, H | 1 |
| Totsuka, O | 1 |
| Yoshinari, D | 1 |
| Sunose, Y | 1 |
| Takeyoshi, I | 1 |
| Peled, Y | 1 |
| Levavi, H | 1 |
| Krissi, H | 1 |
| Weill, Y | 1 |
| Sabah, G | 1 |
| Eitan, R | 1 |
| Eveno, C | 1 |
| Goéré, D | 1 |
| Honoré, C | 1 |
| Dumont, F | 1 |
| Tzanis, D | 1 |
| Benhaim, L | 1 |
| Malka, D | 1 |
| Elias, D | 1 |
| Roussel, H | 1 |
| Markoutsaki, T | 1 |
| Dubreuil, O | 1 |
| Trouilloud, I | 1 |
| Landi, B | 1 |
| Lepère, C | 1 |
| Vaillant, JN | 1 |
| Berger, A | 1 |
| Truter, EJ | 2 |
| Santos, AS | 2 |
| Els, WJ | 2 |
| Rassu, PC | 1 |
| Cassinelli, G | 1 |
| Ronzitti, F | 1 |
| Bronzino, P | 1 |
| Stanizzi, T | 1 |
| Casaccia, M | 1 |
| Garin, L | 1 |
| Corbinais, S | 1 |
| Boucher, E | 1 |
| Blanchot, J | 1 |
| Le Guilcher, P | 1 |
| Raoul, JL | 1 |
| Peng, Z | 5 |
| Lou, J | 2 |
| Wang, H | 4 |
| Tang, Q | 1 |
| van Kuilenburg, AB | 1 |
| Baars, JW | 1 |
| Meinsma, R | 1 |
| van Gennip, AH | 1 |
| Makhnova, EV | 1 |
| Gershanovich, ML | 1 |
| Palmer, DH | 1 |
| Milner, AE | 1 |
| Kerr, DJ | 2 |
| Young, LS | 2 |
| BRINDLEY, CO | 1 |
| MOORE, JG | 1 |
| VANCAMPENHOUT, JL | 1 |
| BRANDKAMP, WW | 1 |
| KABAKOW, B | 1 |
| ALBAUM, H | 1 |
| ANTOPOL, W | 1 |
| BLINICK, G | 1 |
| SUSSMAN, L | 1 |
| GINZBURG, L | 1 |
| CHAN, DP | 1 |
| HO, JH | 1 |
| WOO, AW | 1 |
| GOLLIN, FF | 1 |
| ANSFIELD, FJ | 3 |
| VERMUND, H | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| OGIER, E | 1 |
| MAIJNELLI, M | 1 |
| PERITI, P | 1 |
| Poindessous, V | 1 |
| Koeppel, F | 1 |
| Raymond, E | 4 |
| Cvitkovic, E | 3 |
| Waters, SJ | 1 |
| Larsen, AK | 1 |
| Semiglazov, VF | 1 |
| Maksimov, SIa | 1 |
| Semiglazov, VV | 1 |
| Kosnikov, AG | 1 |
| Tournigand, C | 2 |
| Louvet, C | 6 |
| Molitor, JL | 2 |
| Fritel, X | 1 |
| Dehni, N | 2 |
| Sezeur, A | 2 |
| Pigné, A | 4 |
| Cady, J | 2 |
| Milliez, J | 1 |
| de Gramont, A | 6 |
| Vasey, PA | 1 |
| McMahon, L | 1 |
| Paul, J | 1 |
| Reed, N | 1 |
| Kaye, SB | 1 |
| Kobayashi, K | 1 |
| Fujimoto, S | 1 |
| Takahashi, M | 2 |
| Mutou, T | 1 |
| Toyosawa, T | 1 |
| Ohtsuka, Y | 1 |
| Ogasawara, T | 1 |
| Nishioka, K | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Takahashi, K | 1 |
| Matsumoto, H | 1 |
| Miyamoto, H | 2 |
| Horiguchi, S | 1 |
| Mezawa, S | 1 |
| Homma, H | 1 |
| Doi, T | 1 |
| Akiyama, T | 1 |
| Murakami, K | 1 |
| Kogawa, K | 1 |
| Hirata, K | 1 |
| Kida, M | 1 |
| Murase, K | 1 |
| Iyama, S | 1 |
| Simeoni, M | 1 |
| Magni, P | 1 |
| Cammia, C | 1 |
| De Nicolao, G | 1 |
| Croci, V | 1 |
| Pesenti, E | 1 |
| Germani, M | 1 |
| Poggesi, I | 1 |
| Rocchetti, M | 1 |
| Rischin, D | 1 |
| Phillips, KA | 1 |
| Friedlander, M | 1 |
| Harnett, P | 1 |
| Quinn, M | 1 |
| Richardson, G | 1 |
| Martin, A | 1 |
| Violini, S | 1 |
| D'Ascenzo, S | 1 |
| Millimaggi, D | 1 |
| Miotti, S | 1 |
| Canevari, S | 1 |
| Pavan, A | 1 |
| Dolo, V | 1 |
| Hsu, LC | 1 |
| Lee, RM | 1 |
| White, RL | 1 |
| Chung, I | 1 |
| Deisseroth, AB | 1 |
| Melichar, B | 1 |
| Urminská, H | 1 |
| Kohlová, T | 1 |
| Nová, M | 1 |
| Cesák, T | 1 |
| Sundar, S | 2 |
| Symonds, RP | 1 |
| Decatris, MP | 1 |
| Kumar, DM | 1 |
| Osman, A | 1 |
| Vasanthan, S | 1 |
| O'byrne, KJ | 2 |
| Pectasides, D | 1 |
| Pectasides, M | 1 |
| Farmakis, D | 1 |
| Gaglia, A | 1 |
| Koumarianou, A | 1 |
| Nikolaou, M | 1 |
| Koumpou, M | 1 |
| Kountourakis, P | 1 |
| Papaxoinis, G | 1 |
| Mitrou, P | 1 |
| Economopoulos, T | 1 |
| Raptis, SA | 1 |
| Baba, T | 1 |
| Mandai, M | 1 |
| Fujii, S | 1 |
| Mueck, AO | 1 |
| Wallwiener, D | 1 |
| Huober, J | 1 |
| Li, Q | 1 |
| Yao, Y | 1 |
| Zhang, J | 1 |
| Hasegawa, K | 2 |
| Sawai, T | 1 |
| Kishimoto, Y | 1 |
| Akimoto, T | 1 |
| Garcia, AA | 1 |
| Blessing, JA | 6 |
| Lenz, HJ | 1 |
| Darcy, KM | 1 |
| Mannel, RS | 1 |
| Miller, DS | 1 |
| Husseinzadeh, N | 1 |
| Polyzos, A | 1 |
| Giannikos, L | 1 |
| Agrafiotis, A | 1 |
| Kazaz, M | 1 |
| Zonas, C | 1 |
| Sfikakis, P | 1 |
| Wolf, JK | 1 |
| Bodurka, DC | 1 |
| Verschraegen, C | 2 |
| Sun, CC | 1 |
| Branham, D | 1 |
| Jenkins, AD | 1 |
| Atkinson, N | 1 |
| Gershenson, DM | 2 |
| Carneiro, BA | 1 |
| Kaminer, L | 1 |
| Eldibany, M | 1 |
| Sreekantaiah, C | 1 |
| Kaul, K | 1 |
| Locker, GY | 1 |
| Baek, JH | 1 |
| Kim, JG | 1 |
| Jeon, SB | 1 |
| Chae, YS | 1 |
| Kim, DH | 1 |
| Sohn, SK | 1 |
| Lee, KB | 1 |
| Shin, HJ | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Jung, HY | 1 |
| Yu, W | 1 |
| Neale, G | 1 |
| Qureshi, F | 1 |
| Wright, JD | 1 |
| Hagemann, A | 1 |
| Rader, JS | 1 |
| Viviano, D | 1 |
| Gibb, RK | 1 |
| Norris, L | 1 |
| Mutch, DG | 1 |
| Powell, MA | 1 |
| Zhang, P | 1 |
| Feng, FY | 1 |
| Wu, LY | 1 |
| Hu, Y | 1 |
| Liu, JW | 1 |
| Gao, YJ | 1 |
| Guan, XQ | 1 |
| Nan, KJ | 1 |
| Suo, AL | 1 |
| Wang, XW | 1 |
| Zhang, MH | 1 |
| Zhang, WD | 1 |
| Li, CW | 1 |
| Zhao, JB | 1 |
| Zurabiani, TA | 1 |
| Charkviani, LI | 1 |
| Gersamia, GK | 1 |
| Nakayama, N | 1 |
| Tanabe, S | 1 |
| Koizumi, W | 1 |
| Higuchi, K | 1 |
| Sasaki, T | 1 |
| Nakatani, K | 1 |
| Shimoda, T | 1 |
| Nishimura, K | 1 |
| Kobayashi, N | 1 |
| Mitomi, H | 1 |
| Saigenji, K | 1 |
| Lu, S | 1 |
| Xiao, L | 1 |
| Cai, L | 1 |
| Wang, Z | 1 |
| Rosa, DD | 1 |
| Awada, A | 1 |
| Mano, MS | 1 |
| Selleslags, J | 1 |
| Lebrun, F | 1 |
| Gil, T | 1 |
| Piccart, MJ | 1 |
| D'Hondt, V | 1 |
| Yang, JL | 1 |
| Qu, XJ | 1 |
| Yu, Y | 1 |
| Kohn, EC | 1 |
| Friedlander, ML | 1 |
| Thompson, JP | 1 |
| Dockerty, MB | 1 |
| Symmonds, RE | 2 |
| Hayles, AB | 1 |
| Neijt, JP | 6 |
| ten Bokkel Huinink, WW | 4 |
| van der Burg, ME | 4 |
| van Oosterom, AT | 5 |
| Vriesendorp, R | 1 |
| Kooyman, CD | 1 |
| van Lindert, AC | 3 |
| Hamerlynck, JV | 2 |
| van Lent, M | 2 |
| van Houwelingen, JC | 1 |
| Szepesi, T | 2 |
| Kärcher, KH | 1 |
| Seitz, W | 1 |
| Kogelnik, HD | 1 |
| Reinartz, G | 1 |
| Janisch, H | 1 |
| Szalay, S | 2 |
| Walliser, S | 1 |
| Redmann, K | 1 |
| Del Junco, G | 1 |
| Herson, J | 1 |
| Rutledge, FN | 4 |
| Breitenecker, G | 1 |
| Schratter-Sehn, A | 1 |
| Rogan, AM | 1 |
| Riss, T | 1 |
| Wittich, G | 1 |
| Heckenthaler, W | 1 |
| Fasching, W | 1 |
| Scheiber, V | 1 |
| Maeyama, M | 2 |
| Tayama, C | 1 |
| Inoue, S | 2 |
| Tajima, C | 2 |
| Onizuka, Y | 1 |
| Tanaka, N | 2 |
| Nakayama, M | 2 |
| Iwamasa, T | 1 |
| Schulz, BO | 1 |
| Hof, K | 1 |
| Friedrich, HJ | 1 |
| Weppelmann, B | 1 |
| Krebs, D | 1 |
| Stehman, FB | 1 |
| Ehrlich, CE | 1 |
| Scarabelli, C | 1 |
| Campagnutta, E | 1 |
| Oberfield, RA | 1 |
| Carmo-Pereira, J | 1 |
| Costa, FO | 1 |
| Henriques, E | 1 |
| Ricardo, JA | 1 |
| Benedetti Panici, P | 2 |
| Di Roberto, P | 1 |
| Margariti, PA | 1 |
| Villani, L | 1 |
| Sacco, F | 1 |
| Cognetti, F | 1 |
| Bompiani, A | 1 |
| Krulik, M | 4 |
| Brissaud, P | 1 |
| Sirinelli, A | 1 |
| Hubert, D | 1 |
| Zylberait, D | 1 |
| Debray, J | 1 |
| Myers, CE | 6 |
| Collins, JM | 2 |
| Grönroos, M | 1 |
| Nieminen, U | 2 |
| Kauppila, A | 3 |
| Kauppila, O | 1 |
| Saksela, E | 1 |
| Väyrynen, M | 1 |
| Teufel, G | 1 |
| Myers, C | 1 |
| Hainsworth, JD | 1 |
| Malcolm, A | 1 |
| Johnson, DH | 1 |
| Burnett, LS | 2 |
| Jones, HW | 2 |
| Greco, FA | 3 |
| Takada, M | 2 |
| Morasca, L | 2 |
| Erba, E | 2 |
| Vaghi, M | 1 |
| Ghelardoni, C | 1 |
| Mangioni, C | 2 |
| Sessa, C | 2 |
| Landoni, F | 1 |
| Garattini, S | 2 |
| Noda, T | 1 |
| Kosakai, H | 1 |
| Tsujimura, K | 1 |
| Nakanishi, A | 1 |
| Shintani, M | 1 |
| Kamamoto, Y | 1 |
| Shimamoto, I | 1 |
| Ichijo, M | 1 |
| Bruntsch, U | 2 |
| Gallmeier, WM | 2 |
| ten Berge, RJ | 1 |
| Schellekens, PT | 1 |
| Bruning, PF | 1 |
| Yamagata, S | 1 |
| Unno, T | 1 |
| Yamamoto, K | 1 |
| Sugawa, T | 1 |
| Akiyama, J | 1 |
| Sagara, Y | 1 |
| Takeda, Y | 2 |
| Onnis, A | 1 |
| Maggino, T | 1 |
| Calciati, A | 1 |
| Clerico, M | 1 |
| Donadio, M | 1 |
| Giaccone, G | 1 |
| Dembo, AJ | 1 |
| Ozols, RF | 7 |
| Young, RC | 12 |
| Neville, AJ | 1 |
| Gilchrist, KW | 1 |
| Davis, TE | 3 |
| Speyer, JL | 3 |
| Jenkins, J | 2 |
| Block, JB | 1 |
| Chlebowski, RT | 1 |
| Dietrich, MF | 1 |
| Isacoff, WH | 1 |
| Hashimi, LA | 1 |
| Khalyl, MF | 1 |
| Salem, PA | 1 |
| Valet, G | 1 |
| Warnecke, HH | 1 |
| Kahle, H | 1 |
| Conte, PF | 2 |
| Alama, A | 1 |
| Favoni, R | 1 |
| Trave, F | 1 |
| Rosso, R | 2 |
| Nicolin, A | 1 |
| Brodovsky, HS | 2 |
| Bauer, M | 1 |
| Horton, J | 2 |
| Elson, PJ | 1 |
| Sawada, M | 5 |
| Matsui, Y | 1 |
| Okudaira, Y | 2 |
| Inagaki, J | 1 |
| Ogawa, M | 1 |
| Horikoshi, N | 1 |
| Ezaki, K | 1 |
| Inoue, K | 1 |
| Aiba, K | 1 |
| Komyo, M | 1 |
| Kubo, H | 1 |
| Moresco, L | 1 |
| Quidaciolu, F | 1 |
| Ingravaglieri, E | 1 |
| Sorice, G | 1 |
| Yoshizawa, H | 1 |
| Kanazawa, K | 3 |
| Takeuchi, S | 2 |
| Okamura, Y | 1 |
| Goto, S | 1 |
| Kajiwara, T | 1 |
| Grigorova, TM | 1 |
| Vartanian, LG | 1 |
| Marenich, AF | 1 |
| Pankov, AK | 2 |
| Sidorenko, IuS | 2 |
| Il'inskaia, EG | 2 |
| Ogorodnikova, LS | 1 |
| Zubkova, TV | 2 |
| Julian, CG | 1 |
| Richardson, RL | 1 |
| Burnett, L | 1 |
| Hande, KR | 1 |
| Oldham, RK | 1 |
| Wilson, AP | 1 |
| Neal, FE | 1 |
| De Palo, G | 1 |
| Demicheli, R | 1 |
| Valagussa, P | 1 |
| De Lena, M | 1 |
| Villa, E | 1 |
| Sugimori, H | 1 |
| Tanaka, M | 1 |
| Jimi, S | 1 |
| Watanabe, E | 1 |
| Kato, Y | 1 |
| Morita, T | 1 |
| Shigyo, R | 1 |
| Yamashita, H | 2 |
| Nishimura, A | 1 |
| Kawakami, M | 1 |
| Toyota, Y | 1 |
| Tsukamoto, N | 1 |
| Matsuyama, T | 1 |
| Taki, I | 3 |
| Yajima, A | 1 |
| Mori, T | 1 |
| Wakisaka, T | 1 |
| Sakahira, H | 1 |
| Yamauchi, R | 1 |
| Suzuki, M | 2 |
| Choudhury, K | 1 |
| Chatterjee, SK | 1 |
| Bhattacharya, M | 1 |
| Barlow, JJ | 6 |
| D'Incalci, M | 2 |
| Valente, I | 1 |
| Bolis, G | 1 |
| Colombo, N | 1 |
| Nuutinen, LS | 1 |
| Ryhänen, P | 1 |
| Niinimäki, A | 1 |
| Kivinen, S | 2 |
| Saarela, M | 1 |
| Pakarinen, A | 1 |
| Hollmén, A | 1 |
| Fukuda, O | 1 |
| Tokunaga, T | 1 |
| Pfleiderer, A | 1 |
| Israël, L | 1 |
| Lepage, E | 1 |
| Breau, JL | 1 |
| Aguilera, J | 1 |
| Pouillart, P | 2 |
| Bretaudeau, B | 1 |
| Palangie, T | 2 |
| Jouve, M | 2 |
| Garcia-Giralt, E | 2 |
| Asselain, B | 1 |
| Donehower, RC | 2 |
| Klecker, R | 1 |
| Chabner, BA | 3 |
| Aroney, RS | 1 |
| Levi, JA | 1 |
| Dalley, DN | 1 |
| Miller, AB | 2 |
| Klaassen, DJ | 2 |
| Boyes, DA | 2 |
| Dodds, DJ | 1 |
| Gerulath, A | 2 |
| Kirk, ME | 1 |
| Levitt, M | 2 |
| Pearson, JG | 2 |
| Wall, C | 1 |
| Adams, M | 1 |
| Johansen, KA | 1 |
| James, KW | 1 |
| Rocker, I | 1 |
| Willson, JK | 1 |
| Koike, K | 1 |
| Ohkawa, K | 1 |
| Amasaki, H | 1 |
| Terashima, Y | 2 |
| Birembaut, P | 1 |
| Parjoie, R | 1 |
| Ploton, D | 1 |
| Rebaiz, K | 1 |
| Wolf, C | 1 |
| Woodcock, TM | 1 |
| Martin, DS | 1 |
| Damin, LA | 1 |
| Kemeny, NE | 1 |
| Young, CW | 1 |
| Balconi, G | 1 |
| Ottolenghi, L | 1 |
| Salmona, A | 1 |
| Park, RC | 1 |
| Blom, J | 1 |
| Disaia, PJ | 1 |
| Lagasse, LD | 1 |
| Senn, HJ | 2 |
| Lei, D | 1 |
| Castaño-Almendral, A | 1 |
| Brunner, KW | 1 |
| Martz, G | 1 |
| Obrecht, P | 1 |
| Melchert, F | 1 |
| Rhomberg, W | 1 |
| Dedrick, RL | 1 |
| Brennan, MF | 1 |
| Buckpitt, AR | 1 |
| Londer, H | 1 |
| DeVita, VT | 3 |
| Kamphuis, JT | 1 |
| Huider, MC | 1 |
| Ras, GJ | 1 |
| Verhagen, CA | 1 |
| Kateman, I | 1 |
| Vreeswijk, JH | 1 |
| Burghouts, JT | 1 |
| Bose, CK | 1 |
| Mukherjea, M | 1 |
| Vexler, AM | 1 |
| Mou, X | 1 |
| Gabizon, AA | 1 |
| Gorodetsky, R | 1 |
| Goan, SR | 1 |
| Fichtner, I | 1 |
| Just, U | 1 |
| Karawajew, L | 1 |
| Schultze, W | 1 |
| Krause, KP | 1 |
| von Harsdorf, S | 1 |
| von Schilling, C | 1 |
| Herrmann, F | 1 |
| Zhao, E | 1 |
| Zhou, M | 1 |
| Fu, C | 1 |
| Shen, B | 1 |
| Zhang, Q | 1 |
| Lian, L | 1 |
| Lévi, F | 1 |
| Peláez, I | 1 |
| López, R | 1 |
| Palacio, I | 1 |
| Fernández, Y | 1 |
| Estrada, E | 1 |
| Esteban, E | 1 |
| Buesa, JM | 1 |
| Lacave, AJ | 1 |
| Scheim, DE | 1 |
| Lin, JY | 1 |
| Morgan, RJ | 2 |
| Speyer, J | 2 |
| Doroshow, JH | 2 |
| Margolin, K | 2 |
| Raschko, J | 2 |
| Sorich, J | 1 |
| Akman, S | 1 |
| Leong, L | 2 |
| Somlo, G | 2 |
| Vasilev, S | 1 |
| Cao, Z | 3 |
| You, Z | 1 |
| Zhou, S | 2 |
| Sawada, K | 1 |
| Tan, M | 1 |
| Kanno, M | 1 |
| Oikawa, K | 1 |
| Shibuya, S | 1 |
| Fukura, Y | 1 |
| Kikuchi, T | 1 |
| Hatakeyoma, F | 1 |
| Massad, LS | 1 |
| Wagley, E | 1 |
| Winkelman, L | 1 |
| Lincoln, S | 1 |
| Yordan, EL | 1 |
| de Geest, K | 1 |
| Wilbanks, GD | 1 |
| Look, KY | 2 |
| Muss, HB | 2 |
| Morris, M | 1 |
| Braly, PS | 1 |
| Homesley, HD | 3 |
| Averette, H | 1 |
| Kawai, M | 2 |
| Kikkawa, F | 1 |
| Hattori, S | 1 |
| Ohta, M | 3 |
| Arii, Y | 3 |
| Tomoda, Y | 3 |
| Fredrikson, M | 1 |
| Hursti, TJ | 1 |
| Steineck, G | 1 |
| Fürst, CJ | 1 |
| Börjesson, S | 1 |
| Peterson, C | 1 |
| Sugimura, K | 1 |
| Okizuka, H | 1 |
| Kaji, Y | 1 |
| Ishida, T | 1 |
| Iwanari, O | 3 |
| Kitao, M | 2 |
| Hempling, RE | 1 |
| Piver, MS | 4 |
| Baker, TR | 1 |
| O'Neill Mullen, C | 1 |
| Burnett, AF | 1 |
| Barter, JF | 1 |
| Potkul, RK | 1 |
| Jarvis, T | 1 |
| Barnes, WA | 1 |
| Malmström, H | 1 |
| Carstensen, J | 1 |
| Simonsen, E | 1 |
| Long, HJ | 1 |
| Nelimark, RA | 1 |
| Su, JQ | 1 |
| Garneau, SC | 1 |
| Levitt, R | 1 |
| Goldberg, RM | 1 |
| Poon, MA | 1 |
| Kugler, JW | 1 |
| Velikova, M | 1 |
| Tsvekova, V | 1 |
| Koĭnov, K | 1 |
| Ohsako, M | 1 |
| Sakoda, K | 1 |
| Tabata, M | 2 |
| Mizouchi, J | 1 |
| Sakamoto, H | 1 |
| Yamaguchi, A | 1 |
| Misono, T | 1 |
| Uchizono, H | 1 |
| Yano, T | 1 |
| Harada, O | 1 |
| Mäenpää, JU | 1 |
| Heinonen, E | 2 |
| Karnani, P | 1 |
| Kuoppala, T | 1 |
| Salmi, T | 1 |
| Sipilä, P | 2 |
| Priest, DG | 2 |
| Schmitz, JC | 1 |
| Bunni, MA | 1 |
| Reichman, B | 2 |
| Hakes, T | 2 |
| Rubin, S | 2 |
| Jones, W | 2 |
| Curtin, J | 1 |
| Barakat, R | 1 |
| Almadrones, L | 1 |
| Lewis, JL | 3 |
| Hoskins, W | 2 |
| Higashihara, J | 1 |
| Berens, ME | 1 |
| Collins, LA | 1 |
| Welander, CE | 2 |
| Islam, MQ | 1 |
| Köpf, I | 1 |
| Levan, A | 1 |
| Granberg, S | 1 |
| Friberg, LG | 1 |
| Levan, G | 1 |
| Tuxen, MK | 1 |
| Lund, B | 2 |
| Hansen, OP | 1 |
| Hansen, M | 2 |
| Dorval, T | 1 |
| Beuzeboc, P | 1 |
| Livartowski, A | 1 |
| Nasr, MF | 1 |
| Kemp, GM | 1 |
| Given, FT | 1 |
| Préfontaine, M | 1 |
| Donovan, JT | 1 |
| Powell, JL | 1 |
| Buley, L | 1 |
| Solimando, DA | 1 |
| Phillips, ET | 1 |
| Weiss, RB | 1 |
| Dawson, NA | 1 |
| Diehl, LF | 1 |
| Rickles, NM | 1 |
| Li, J | 1 |
| Hui, N | 1 |
| Zhu, L | 1 |
| Wu, L | 1 |
| Wu, A | 1 |
| Jiang, K | 1 |
| Parmar, MK | 1 |
| Stewart, LA | 1 |
| Altman, DG | 1 |
| Kano, Y | 1 |
| Akutsu, M | 1 |
| Tsunoda, S | 1 |
| Ando, J | 1 |
| Matsui, J | 1 |
| Suzuki, K | 1 |
| Ikeda, T | 1 |
| Inoue, Y | 1 |
| Adachi, K | 1 |
| Kaneyasu, Y | 1 |
| Okawa, MK | 1 |
| Kokubo, N | 1 |
| Takemoto, M | 1 |
| Karasawa, K | 1 |
| Fukuhara, N | 1 |
| Toda, J | 1 |
| Okawa, T | 1 |
| Balat, O | 1 |
| Kudelka, AP | 1 |
| Edwards, CL | 1 |
| Kavanagh, JJ | 1 |
| Djelloul, S | 2 |
| Buquet-Fagot, C | 2 |
| Mester, J | 2 |
| Gespach, C | 2 |
| Abe, H | 1 |
| Tsunaga, N | 1 |
| Yamashita, S | 1 |
| Ishiguro, K | 1 |
| Mitani, I | 1 |
| Kievit, E | 1 |
| Pinedo, HM | 3 |
| Schlüper, HM | 1 |
| Haisma, HJ | 1 |
| Boven, E | 1 |
| Kimura, E | 1 |
| Niimi, S | 1 |
| Watanabe, A | 1 |
| Tanaka, T | 1 |
| Harstrick, A | 1 |
| Vanhoefer, U | 1 |
| Heidemann, A | 1 |
| Druyen, H | 1 |
| Wilke, H | 1 |
| Seeber, S | 1 |
| Athanassiadou, P | 1 |
| Athanassiades, P | 1 |
| Petrakakou, E | 1 |
| Zerva, C | 1 |
| Mavrikakis, M | 1 |
| Soulié, P | 1 |
| Brienza, S | 1 |
| Allain, P | 1 |
| Tortora, G | 1 |
| Caputo, R | 1 |
| Damiano, V | 1 |
| Bianco, R | 1 |
| Pepe, S | 1 |
| Pomatico, G | 1 |
| Bianco, AR | 1 |
| Jiang, Z | 1 |
| Agrawal, S | 1 |
| Ciardiello, F | 1 |
| Grosse, PY | 1 |
| Bressolle, F | 1 |
| Pinguet, F | 1 |
| Zhang, D | 2 |
| Christodoulou, CV | 1 |
| Eliopoulos, AG | 1 |
| Hodgkins, L | 1 |
| Ferry, DR | 1 |
| Viale, M | 1 |
| Pastrone, I | 1 |
| Pellecchia, C | 1 |
| Vannozzi, MO | 1 |
| Cafaggi, S | 1 |
| Esposito, M | 1 |
| Onda, T | 1 |
| Yoshikawa, H | 1 |
| Yasugi, T | 1 |
| Mishima, M | 1 |
| Nakagawa, S | 1 |
| Yamada, M | 2 |
| Matsumoto, K | 1 |
| Taketani, Y | 1 |
| Mundt, AJ | 1 |
| Rotmensch, J | 2 |
| Waggoner, S | 1 |
| Quiet, C | 1 |
| Fleming, G | 1 |
| Saito, A | 1 |
| Yamashita, T | 1 |
| Mariko, Y | 1 |
| Nosaka, Y | 1 |
| Tsuchiya, K | 1 |
| Ando, T | 1 |
| Suzuki, T | 1 |
| Tsuruo, T | 1 |
| Nakanishi, O | 1 |
| Cavaliere, F | 1 |
| Di Filippo, F | 1 |
| Cosimelli, M | 1 |
| Aloe, L | 1 |
| Arcuri, E | 1 |
| Anzà, M | 1 |
| Callopoli, A | 1 |
| Di Lauro, L | 1 |
| Morace, E | 1 |
| Botti, C | 1 |
| Natoli, S | 1 |
| Tedesco, M | 1 |
| Giunta, S | 1 |
| Cavaliere, R | 1 |
| Shimizu, Y | 5 |
| Hasumi, K | 5 |
| Kusaba, H | 1 |
| Mitsugi, K | 1 |
| Nakano, S | 1 |
| Saijo, N | 1 |
| Ochiai, K | 1 |
| Sakaihara, M | 1 |
| Sakai, K | 3 |
| Hara, Y | 1 |
| Kataoka, S | 1 |
| Hanatani, K | 1 |
| Hareyama, H | 1 |
| Khayat, D | 1 |
| Antoine, EC | 1 |
| Coeffic, D | 1 |
| Braly, P | 1 |
| Shibata, S | 1 |
| McNamara, M | 1 |
| Longmate, J | 1 |
| Schinke, S | 1 |
| Nagasawa, S | 1 |
| Kogut, N | 1 |
| Najera, L | 1 |
| Johnson, D | 1 |
| Gory-Delabaere, G | 1 |
| Cupissol, D | 1 |
| Brès, J | 1 |
| Gau, F | 1 |
| Constans, B | 1 |
| Nouguier-Soulé, J | 1 |
| McNamee, D | 1 |
| Yang, TS | 1 |
| Hsu, KC | 1 |
| Tang, R | 1 |
| Chang, TC | 1 |
| Katoh, M | 1 |
| Koninkx, J | 1 |
| Schumacher, U | 1 |
| Culy, CR | 1 |
| Clemett, D | 1 |
| Wiseman, LR | 1 |
| Ohta, I | 1 |
| Gorai, I | 1 |
| Miyamoto, Y | 1 |
| Zheng, JH | 1 |
| Kawata, N | 1 |
| Hirahara, F | 1 |
| Shirotake, S | 1 |
| Swiatkowska-Freund, M | 1 |
| Preis, K | 1 |
| Emerich, J | 1 |
| Heise, C | 1 |
| Lemmon, M | 1 |
| Kirn, D | 1 |
| Chen, R | 1 |
| Pan, L | 1 |
| Peng, XY | 1 |
| Won, JH | 1 |
| Rutherford, T | 1 |
| Fujii, T | 1 |
| Zelterman, D | 1 |
| Pizzorno, G | 1 |
| Sapi, E | 1 |
| Leavitt, J | 1 |
| Kacinski, B | 1 |
| Crystal, R | 1 |
| Schwartz, P | 1 |
| Deisseroth, A | 1 |
| Twelves, C | 1 |
| Lejeune, V | 1 |
| Marpeau, L | 1 |
| Jakesz, R | 1 |
| Hausmaninger, H | 2 |
| Samonigg, H | 1 |
| Janni, W | 1 |
| Rjosk, D | 1 |
| Strobl, B | 1 |
| Bergauer, F | 1 |
| Linka, F | 1 |
| Dimpfl, T | 1 |
| Schindlbeck, C | 1 |
| Rack, B | 1 |
| Kaestner, R | 1 |
| Sommer, H | 1 |
| Fujiwaki, R | 1 |
| Hata, K | 1 |
| Nakayama, K | 3 |
| Moriyama, M | 3 |
| Katabuchi, H | 1 |
| Okamura, H | 1 |
| Sakai, E | 1 |
| Miyazaki, K | 1 |
| Fox, RM | 1 |
| Woods, RL | 1 |
| Tattersall, MH | 1 |
| Brodie, GM | 1 |
| Hubbard, SP | 2 |
| Fisher, RI | 3 |
| Bender, RA | 1 |
| Anderson, T | 1 |
| Simon, RM | 2 |
| Canellos, GP | 2 |
| Vendrik, CP | 1 |
| Roozendaal, KJ | 1 |
| Struyvenberg, A | 1 |
| Garvin, AJ | 1 |
| Costa, J | 1 |
| Alberts, DS | 4 |
| Hilgers, RD | 2 |
| Moon, TE | 2 |
| Martimbeau, PW | 1 |
| Rivkin, S | 1 |
| Dunnick, NR | 1 |
| Jones, RB | 1 |
| Doppman, JL | 1 |
| Mattern, J | 2 |
| Kaufmann, M | 1 |
| Hinderer, H | 1 |
| Wayss, K | 2 |
| Volm, M | 2 |
| Pagano, M | 2 |
| Falkson, G | 2 |
| Creech, R | 1 |
| Arseneau, JC | 2 |
| Brodovsky, H | 1 |
| Slayton, RW | 1 |
| Greenspan, E | 1 |
| Davy, M | 1 |
| Mossige, J | 1 |
| Johannessen, JV | 1 |
| Stanhope, CR | 1 |
| Smith, JP | 9 |
| Rutledge, F | 6 |
| Reimer, RR | 1 |
| Hoover, R | 1 |
| Fraumeni, JF | 1 |
| Lewis, GC | 2 |
| Blessing, J | 1 |
| Kardinal, CG | 1 |
| Luce, JK | 2 |
| Barber, HR | 1 |
| Kwon, T | 1 |
| Buterman, I | 1 |
| Kakarla, R | 1 |
| Sablińska, B | 1 |
| Cześnin, K | 1 |
| Ploch, E | 1 |
| Yakushiji, M | 1 |
| Ide, K | 1 |
| Nishimura, H | 1 |
| Nishida, T | 1 |
| Kato, T | 1 |
| Rózewicki, S | 1 |
| Rzepka, I | 1 |
| Górski, H | 1 |
| Ebeling, K | 1 |
| Spitzbart, H | 1 |
| Battelli, T | 1 |
| Manocchi, P | 1 |
| Lele, SB | 2 |
| Dimitriades, M | 1 |
| Papadimitriou, GC | 1 |
| Razis, DV | 1 |
| Panopoulos, C | 1 |
| Midoulas, N | 1 |
| Tuchmann, A | 1 |
| Kerstan, E | 1 |
| Euler-Rolle, J | 1 |
| Eckert, M | 1 |
| Gerassimidis, T | 1 |
| Schultess, F | 1 |
| Hammann, J | 1 |
| Beck, I | 1 |
| Möhlen, KH | 1 |
| Beller, FK | 1 |
| Curry, SL | 1 |
| Gallagher, HS | 1 |
| Berry, RJ | 1 |
| Laing, AH | 1 |
| Wells, J | 1 |
| Serrou, B | 1 |
| Dubois, JB | 1 |
| Birbraer, VM | 1 |
| Ogorodnikova, IS | 1 |
| Gaĭrabed'iants, NG | 1 |
| Piver, S | 1 |
| Chung, WS | 1 |
| Lee, FT | 1 |
| Vongtama, V | 2 |
| Bearden, JD | 1 |
| Coltman, CA | 1 |
| Costanzi, JJ | 1 |
| Saiki, JH | 1 |
| Balcerzak, SP | 1 |
| Rivkin, SE | 2 |
| Morrison, FS | 1 |
| Lane, M | 1 |
| Spigel, SC | 1 |
| Rao, B | 1 |
| Wanebo, HJ | 1 |
| Ochoa, M | 2 |
| Oettgen, HF | 1 |
| Izbicki, RM | 1 |
| Baker, LH | 1 |
| Samson, MK | 1 |
| McDonald, B | 1 |
| Vaitkevicius, VK | 2 |
| Marzotko, F | 2 |
| Krafft, W | 2 |
| Preibsch, W | 1 |
| Schröder, M | 1 |
| Baumgartner, G | 1 |
| Siebner, H | 1 |
| Weber, W | 2 |
| Plaude, RK | 1 |
| Osman, VI | 1 |
| Tabachnik, BI | 1 |
| Purinia, IZh | 1 |
| Gutman, EKh | 1 |
| Forney, JP | 1 |
| Di Saia, PJ | 1 |
| Morrow, CP | 1 |
| Lee, FJ | 1 |
| Ehrhart, H | 2 |
| Frank, S | 1 |
| Richter, K | 1 |
| Penning, W | 1 |
| Meister, P | 1 |
| Schmidt, D | 1 |
| Götz, A | 1 |
| Hreshchyshyn, MM | 1 |
| Kuipers, T | 1 |
| Chen, WC | 1 |
| DeGeest, K | 1 |
| Demuynck, B | 2 |
| Varette, C | 2 |
| Beerblock, K | 1 |
| Bennamoun, M | 1 |
| Tatsuki, Y | 1 |
| Fujimoto, I | 4 |
| Yamauchi, K | 4 |
| Masubuchi, K | 3 |
| Scambia, G | 1 |
| Salerno, MG | 1 |
| Baiocchi, G | 1 |
| Cento, R | 1 |
| Mancuso, S | 1 |
| Reed, E | 1 |
| Jacob, J | 1 |
| Allegra, C | 1 |
| Hasegawa, E | 1 |
| Watanabe, H | 1 |
| Ohmura, G | 1 |
| Hirakawa, S | 1 |
| Momose, K | 1 |
| Inoue, M | 2 |
| Nakanishi, K | 2 |
| Ueda, G | 3 |
| Tanizawa, O | 3 |
| Dempke, WC | 2 |
| Hosking, LK | 2 |
| Hill, BT | 2 |
| Covens, A | 1 |
| O'Connell, G | 1 |
| Rusthoven, J | 1 |
| Mazurka, J | 1 |
| Shellard, SA | 1 |
| Fichtinger-Schepman, AM | 1 |
| Tone, T | 1 |
| Scanlon, KJ | 4 |
| Whelan, RD | 1 |
| Akamatsu, K | 1 |
| Endo, K | 1 |
| Tsunenari, T | 1 |
| Matsumoto, T | 1 |
| Kaiho, S | 1 |
| Morikawa, K | 1 |
| Koizumi, M | 1 |
| Mitsui, H | 1 |
| Koizumi, K | 1 |
| de Graeff, A | 1 |
| van Hoef, ME | 1 |
| Tjia, P | 1 |
| Heintz, AP | 3 |
| Novikova, EG | 1 |
| Borisov, VI | 1 |
| Dmitriev, DG | 2 |
| Zel'vin, BM | 1 |
| Karseladze, AI | 1 |
| Shchitkov, KG | 1 |
| Li, AD | 1 |
| Miwa, M | 1 |
| Sekiguchi, F | 1 |
| Akaza, H | 1 |
| Tokita, H | 2 |
| Nitta, K | 1 |
| Adachi, S | 2 |
| Ishitsuka, H | 1 |
| Willemse, PH | 1 |
| Vermorken, JB | 1 |
| Aartsen, E | 1 |
| Noda, K | 1 |
| Watanabe, Y | 1 |
| Ikeda, M | 1 |
| Takeuchi, K | 1 |
| Kinugasa, M | 1 |
| Sekiba, K | 1 |
| Kobashi, Y | 1 |
| Ohiwa, T | 1 |
| Odagiri, H | 1 |
| Gerhardt, RT | 1 |
| Perras, JP | 1 |
| Sevin, BU | 2 |
| Petru, E | 2 |
| Ramos, R | 2 |
| Guerra, L | 1 |
| Averette, HE | 2 |
| Ryuko, K | 1 |
| Nakayama, S | 1 |
| Miyako, J | 1 |
| Nakayama, T | 1 |
| Nakai, Y | 1 |
| Tamura, H | 1 |
| Nagano, T | 1 |
| Shibamoto, T | 1 |
| Ohara, A | 1 |
| Ozawa, M | 1 |
| Kurata, A | 1 |
| Hansen, LA | 1 |
| Hughes, TE | 1 |
| Aoki, Y | 1 |
| Takakuwa, K | 1 |
| Kodama, S | 1 |
| Tokunaga, A | 1 |
| Takahashi, T | 1 |
| Weber, G | 1 |
| Nagai, M | 1 |
| Prajda, N | 1 |
| Nakamura, H | 1 |
| Szekeres, T | 1 |
| Olah, E | 1 |
| Nordlinger, B | 1 |
| Maisani, JE | 1 |
| Lagadec, B | 1 |
| Delfau, S | 1 |
| Gonzalez-Canali, G | 1 |
| Cherchi, PL | 1 |
| Bagella, MP | 1 |
| Campiglio, A | 1 |
| Rubattu, A | 1 |
| Farina, M | 1 |
| Ambrosini, A | 1 |
| Yamasaki, M | 1 |
| Urabe, T | 1 |
| Ozaki, M | 3 |
| Yanagita, T | 2 |
| Takayama, K | 2 |
| Chen, JT | 3 |
| Yokosuka, K | 1 |
| Teshima, H | 2 |
| Hirai, Y | 2 |
| Hamada, T | 2 |
| van der Hoop, RG | 1 |
| van Houwelingen, C | 1 |
| Lisetskiĭ, VA | 1 |
| Evtushenko, GV | 1 |
| Dotsenko, IuS | 1 |
| Svintsitskiĭ, VS | 1 |
| Hansen, HH | 2 |
| Thomsen, HK | 1 |
| Sørensen, BL | 2 |
| Nielsen, NC | 2 |
| Lundvall, F | 2 |
| Chen, KT | 1 |
| Hrushesky, WJ | 1 |
| Hirabayashi, K | 1 |
| Arakawa, A | 1 |
| Kato, N | 1 |
| Asai, H | 1 |
| Yasui, Y | 2 |
| Suzumori, K | 3 |
| Yagami, Y | 2 |
| Ludescher, C | 1 |
| Weger, AR | 1 |
| Lindholm, J | 1 |
| Oefner, D | 1 |
| Reitsamer, R | 1 |
| Mikuz, G | 1 |
| Martoni, A | 1 |
| Ercolino, L | 1 |
| Bellucco, A | 1 |
| Canova, N | 1 |
| Lelli, G | 1 |
| Pannuti, F | 1 |
| Usui, N | 1 |
| Yoshida, K | 1 |
| Hirayama, H | 1 |
| Takeuchi, H | 1 |
| Wada, H | 1 |
| Iwasa, T | 1 |
| Yamamoto, T | 2 |
| Nagasawa, I | 1 |
| Nakazawa, A | 1 |
| Shimizu, H | 1 |
| Saitoh, J | 1 |
| Tanaka, Y | 2 |
| Prosperi Porta, R | 1 |
| Rulli, G | 1 |
| Giovagnoli, MR | 1 |
| Carenza, L | 1 |
| Perras, J | 1 |
| Boike, G | 1 |
| Nguyen, H | 1 |
| Chu, E | 1 |
| Lai, GM | 1 |
| Zinn, S | 1 |
| Allegra, CJ | 1 |
| Ihara, T | 1 |
| Hisamatsu, K | 1 |
| Okamoto, E | 1 |
| Suemitsu, H | 1 |
| Matsuda, M | 1 |
| Nanba, K | 1 |
| Kirimoto, K | 1 |
| Sagawa, T | 1 |
| Yamashita, K | 1 |
| Kawamura, M | 1 |
| Shimizu, T | 1 |
| Haga, H | 1 |
| Yorozu, Y | 1 |
| Kasamo, M | 1 |
| Fujita, M | 1 |
| Takamizawa, H | 1 |
| Sekiya, S | 1 |
| Iwasawa, H | 1 |
| Ishige, H | 1 |
| Miyake, H | 1 |
| Kohno, M | 1 |
| Nishiyama, S | 1 |
| Inoue, H | 1 |
| Ikeuchi, H | 1 |
| Sekigawa, S | 1 |
| Matsunaga, S | 1 |
| Werquin, S | 1 |
| Kacet, S | 1 |
| Caron, J | 1 |
| Lacroix, D | 1 |
| Libersa, C | 1 |
| Coget, JM | 1 |
| Lekieffre, J | 1 |
| Inagaki, S | 1 |
| Imaizumi, H | 1 |
| Kakihara, M | 1 |
| Gröhn, P | 1 |
| Vesala, J | 1 |
| Kikuchi, Y | 4 |
| Oomori, K | 3 |
| Iwano, I | 3 |
| Kizawa, I | 3 |
| Miyauchi, M | 3 |
| Kita, T | 3 |
| Kuki, E | 1 |
| Kato, K | 2 |
| Niemiec, TR | 1 |
| Senekjian, EK | 1 |
| Montag, AG | 1 |
| Yuzawa, H | 2 |
| Knüsli, C | 1 |
| Ruff, P | 1 |
| Laffer, U | 1 |
| Stoll, HR | 1 |
| Obrist, R | 1 |
| Obrecht, JP | 1 |
| Rusakov, IG | 1 |
| Chissov, VN | 1 |
| Antoshechkina, ET | 1 |
| Ze'lvin, BM | 1 |
| Kano, T | 2 |
| Kaesemann, H | 1 |
| Caffier, H | 1 |
| Rotte, K | 1 |
| Griffin, TW | 1 |
| Hunter, RA | 1 |
| Cederbaum, AI | 1 |
| Tak, WK | 1 |
| Ward, AD | 1 |
| Schwartz, JH | 1 |
| Halpin, TF | 1 |
| Strauss, GM | 1 |
| Meyer, RN | 1 |
| Liepman, MK | 1 |
| Myoga, H | 1 |
| Tamaki, M | 1 |
| Shinko, Y | 1 |
| Ohta, S | 1 |
| Shigemasa, K | 1 |
| Nogawa, T | 1 |
| Katsube, Y | 1 |
| Fujiwara, A | 2 |
| Walton, LA | 1 |
| de Bruijn, EA | 1 |
| Tjaden, UR | 1 |
| Reeuwijk, HJ | 1 |
| Goodman, HM | 1 |
| Dottino, PR | 1 |
| Kredenster, D | 1 |
| Mark, M | 1 |
| Runowicz, C | 1 |
| Cohen, CJ | 1 |
| Sertoli, MR | 1 |
| Bruzzone, M | 1 |
| Rubagotti, A | 1 |
| Bentivoglio, G | 1 |
| Conio, A | 1 |
| Pescetto, G | 1 |
| Emrich, LJ | 1 |
| Schneider, T | 1 |
| Lotze, W | 6 |
| Grosh, WW | 1 |
| Belinson, JL | 1 |
| Pretorius, RG | 1 |
| McClure, M | 1 |
| Ashikaga, T | 1 |
| Drolet, Y | 1 |
| Dray, C | 1 |
| Lavoie, A | 1 |
| Painchaud, M | 1 |
| Blouin, R | 1 |
| Tessier, C | 1 |
| Laufman, LR | 1 |
| Green, JB | 1 |
| O'Toole, R | 1 |
| Young, DC | 1 |
| Lin, F | 1 |
| Nagai, S | 2 |
| Kamiya, H | 2 |
| Sato, K | 1 |
| Louie, KG | 1 |
| Ostchega, Y | 1 |
| Howser, D | 1 |
| Fukuda, K | 1 |
| Sakamoto, A | 1 |
| Wu, BZ | 1 |
| Inagaki, M | 2 |
| Hongo, J | 2 |
| Hirota, Y | 2 |
| Arimoto, Y | 1 |
| Wada, T | 1 |
| Yoshiya, N | 1 |
| Misawa, Y | 1 |
| Ishida, M | 1 |
| Trimbos, JB | 1 |
| Schaberg, A | 1 |
| Van der Velde, EA | 1 |
| Nooy, M | 1 |
| Garcia-Kendall, D | 1 |
| Surwit, EA | 1 |
| Sugita, M | 1 |
| Tenjin, Y | 1 |
| Pommier, RF | 1 |
| Woltering, EA | 1 |
| Milo, G | 1 |
| Fletcher, WS | 2 |
| Lu, Y | 3 |
| Kashani-Sabet, M | 2 |
| Ma, J | 1 |
| Newman, E | 1 |
| Richter, P | 4 |
| Sarembe, B | 4 |
| Chylak, V | 1 |
| Kolarić, K | 1 |
| Krusić, J | 1 |
| Newman, EM | 2 |
| Kesavan, V | 1 |
| Takizawa, K | 1 |
| Ino, Y | 1 |
| Isono, T | 1 |
| Sato, M | 1 |
| Yokoo, I | 1 |
| Iguchi, T | 1 |
| Kamata, H | 1 |
| Murakami, A | 1 |
| Miyagawa, N | 1 |
| Yasui, H | 1 |
| Nagano, H | 1 |
| Abe, S | 1 |
| Ueda, K | 1 |
| Kisida, S | 1 |
| Liu, LY | 1 |
| Hong, WJ | 1 |
| Hou, YJ | 1 |
| Yao, ZH | 1 |
| Wu, AR | 1 |
| Li, L | 1 |
| Paschal, BR | 1 |
| Fujisawa, S | 1 |
| Rosenshein, NB | 1 |
| Ettinger, DS | 1 |
| Brökelmann, J | 1 |
| Hartlapp, JH | 1 |
| N'Koua-M'Bon, JB | 1 |
| Cardorelle, A | 1 |
| Paraiso, ID | 1 |
| Gombe-M'balawa, CH | 1 |
| Potapov, SL | 1 |
| Korman, DB | 1 |
| Shamaev, VI | 1 |
| Ershova, RB | 1 |
| Makarov, OV | 1 |
| Akagaki, E | 1 |
| Hirota, K | 1 |
| Kono, M | 1 |
| Irie, T | 1 |
| Miura, S | 1 |
| Theissig, P | 1 |
| Theissig, F | 1 |
| Aabo, K | 1 |
| Hald, I | 1 |
| Hørbov, S | 1 |
| Dombernowsky, P | 1 |
| Sørensen, HM | 1 |
| Dinse, GE | 1 |
| Creech, RH | 1 |
| Greenspan, EM | 1 |
| Hahn, RG | 1 |
| Posada, JG | 1 |
| Marantz, AB | 1 |
| Yeung, KY | 1 |
| Smith, FP | 2 |
| Delgado, G | 2 |
| Edwards, BK | 1 |
| Schein, PS | 2 |
| McLaughlin, EK | 1 |
| Tuholski, N | 1 |
| Sawada, T | 1 |
| Tsukasaki, K | 1 |
| Fujiya, S | 1 |
| Yasuda, M | 1 |
| Tahira, K | 1 |
| Nakabayashi, Y | 1 |
| Yoshioka, M | 1 |
| Hatiya, S | 1 |
| Lucas, WE | 1 |
| Howell, SB | 1 |
| Pasmantier, MW | 1 |
| Coleman, M | 1 |
| Silver, RT | 1 |
| Ballard, WP | 1 |
| Young, L | 1 |
| Mason, N | 1 |
| Salmon, SE | 1 |
| Fuller, AF | 1 |
| Krane, IM | 1 |
| Budzik, GP | 1 |
| Donahoe, PK | 1 |
| Carlson, JA | 1 |
| Day, TG | 1 |
| Botts, B | 1 |
| Masterson, BJ | 1 |
| Franz, G | 1 |
| Lietz, H | 1 |
| Chambers, JT | 1 |
| Schwartz, PE | 1 |
| Lobova, TG | 1 |
| Lichinitser, MR | 1 |
| Dobrynin, IaV | 1 |
| Nikolaeva, TG | 1 |
| Zharkov, SA | 1 |
| Montoneri, C | 1 |
| Garozzo, G | 1 |
| Granà, G | 1 |
| Castro, R | 1 |
| Panella, M | 1 |
| Granata, D | 1 |
| La Greca, M | 1 |
| Sakakibara, K | 1 |
| Casanova, H | 1 |
| Nishida, Y | 1 |
| Kazato, S | 1 |
| Miyazaki, T | 1 |
| Umemura, S | 1 |
| Paule, B | 1 |
| Frydman, R | 1 |
| Chasseray, JM | 1 |
| Simon, G | 1 |
| Brunet, R | 1 |
| Chauvergne, J | 1 |
| Sutow, WW | 1 |
| Omura, GA | 1 |
| Villasanta, U | 1 |
| Bloedorn, FG | 1 |
| Griffen, WO | 1 |
| Humphrey, L | 1 |
| Sosin, H | 1 |
| Limber, GK | 1 |
| King, RE | 1 |
| Silverberg, SG | 1 |
| Berenbaum, MC | 1 |
| Sheard, CE | 1 |
| Reittie, JR | 1 |
| Bundick, RV | 1 |
| Clark, DG | 1 |
| Hilaris, BS | 1 |
| Freel, JH | 1 |
| Armstrong, JG | 1 |
| Bloomfield, RD | 1 |
| Massey, WH | 1 |
| Dennis, DL | 1 |
| Wood, DC | 1 |
| Speckhard, ME | 1 |
| Hurley, JD | 1 |
| Fetherston, WC | 1 |
| Grueninger, AJ | 1 |
| Wharton, JT | 1 |
| Rieche, K | 1 |
| Mackman, S | 1 |
| Ramirez, G | 1 |
| Curreri, AR | 1 |
| Malkasian, GD | 5 |
| Webb, MJ | 2 |
| Jorgensen, EO | 2 |
| Hecker, D | 1 |
| Klug, H | 1 |
| Tanneberger, S | 1 |
| Rose, H | 1 |
| Carbone, PP | 1 |
| Decker, DG | 3 |
| Kaslow, RA | 1 |
| Wisch, N | 1 |
| Glass, JL | 1 |
| Merkulov, MF | 2 |
| Leskova, SG | 2 |
| Merkulov, M | 1 |
| Leskova, S | 1 |
| Lokich, JJ | 1 |
| Skarin, AT | 1 |
| Preibsche, W | 1 |
| Schwartz, EE | 1 |
| Sklaroff, DM | 1 |
| Levick, SN | 1 |
| Mussey, E | 2 |
| Johnson, CE | 2 |
| Mannes, P | 1 |
| Derriks, R | 1 |
| Moens, R | 1 |
| Heynen, E | 1 |
| Nechaeva, ID | 1 |
| Pol'kina, RI | 1 |
| Szlazak, W | 2 |
| Dipont, E | 1 |
| al-Sarraf, M | 2 |
| Vaughn, CB | 2 |
| Reed, ML | 2 |
| Vaitkevicious, VK | 1 |
| Wolberg, WH | 1 |
| Bateman, JR | 1 |
| Pugh, RP | 1 |
| Cassidy, FR | 1 |
| Marshall, GJ | 1 |
| Irwin, LE | 1 |
| Hanham, IW | 1 |
| Newton, KA | 1 |
| Westbury, G | 1 |
| Meriwether, WD | 1 |
| Ramsey, HE | 1 |
| Ward, SP | 1 |
| Wong, P | 1 |
| Sardesai, S | 1 |
| Alberto, P | 1 |
| Jacobs, EM | 1 |
| Wood, DA | 1 |
| Vaitkevicus, VK | 1 |
| Talley, RW | 1 |
| Loo, RV | 1 |
| Beckett, VL | 1 |
| Motta, R | 1 |
| Dipont, T | 1 |
| Clarkson, B | 1 |
| Ota, K | 1 |
| Ohkita, T | 1 |
| O'Connor, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer.[NCT00403429] | Phase 2 | 36 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer[NCT00006812] | Phase 2 | 0 participants | Interventional | 2001-03-31 | Terminated | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis[NCT00001332] | Phase 1 | 50 participants | Interventional | 1992-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
36 reviews available for fluorouracil and Ovarian Neoplasms
| Article | Year |
|---|---|
Discovery of asymptomatic Krukenberg tumors diagnosed during caesarean section: therapy with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2013 |
Discovery of asymptomatic Krukenberg tumors diagnosed during caesarean section: therapy with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2013 |
[Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplas | 2015 |
[Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplas | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2015 |
[Primary adenocarcinoma of the appendix. Case report and review of the literature].
Topics: Adenocarcinoma; Adult; Appendectomy; Appendiceal Neoplasms; Appendicitis; Cecal Neoplasms; Chemother | 2002 |
[Primary adenocarcinoma of the appendix. Case report and review of the literature].
Topics: Adenocarcinoma; Adult; Appendectomy; Appendiceal Neoplasms; Appendicitis; Cecal Neoplasms; Chemother | 2002 |
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Ep | 2004 |
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Ep | 2004 |
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; | 2004 |
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; | 2004 |
Pharmacology of intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Metabol | 1983 |
Pharmacology of intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Metabol | 1983 |
The use of intraperitoneal chemotherapy in the treatment of ovarian cancer.
Topics: Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans; | 1984 |
The use of intraperitoneal chemotherapy in the treatment of ovarian cancer.
Topics: Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans; | 1984 |
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
Chemotherapy of ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo | 1984 |
Chemotherapy of ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo | 1984 |
Folate metabolites as modulators of antitumor drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biotransformation; Cell Line; | 1993 |
Folate metabolites as modulators of antitumor drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biotransformation; Cell Line; | 1993 |
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 1996 |
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 1996 |
[Anticancer drug-induced colitis--case report and review of the literature].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colitis; Colonoscopy; Drug A | 1997 |
[Anticancer drug-induced colitis--case report and review of the literature].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colitis; Colonoscopy; Drug A | 1997 |
[Oxaliplatin: the first DACH platinum in clinical practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 1997 |
[Oxaliplatin: the first DACH platinum in clinical practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 1997 |
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Division; Cisplatin; Colonic Neopl | 1998 |
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Division; Cisplatin; Colonic Neopl | 1998 |
[Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1999 |
[Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1999 |
[Problems and prospects for combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; Fluor | 1999 |
[Problems and prospects for combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; Fluor | 1999 |
[Gynecologic cancer-evidenced based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Evidence-Based Medicine; Femal | 2000 |
[Gynecologic cancer-evidenced based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Evidence-Based Medicine; Femal | 2000 |
Taxol in the management of cancers of the breast and the ovary.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Taxol in the management of cancers of the breast and the ovary.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; C | 2000 |
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; C | 2000 |
Vision of the future: capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2001 |
Vision of the future: capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2001 |
Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2002 |
Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2002 |
Chemotherapy of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Fluoroura | 1978 |
Chemotherapy of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Fluoroura | 1978 |
Chemotherapy of ovarian cancer: past and present.
Topics: Acrylates; Alkylating Agents; Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Do | 1975 |
Chemotherapy of ovarian cancer: past and present.
Topics: Acrylates; Alkylating Agents; Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Do | 1975 |
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1991 |
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1991 |
Altretamine.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1991 |
Altretamine.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1991 |
[Treatment of advanced ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1990 |
[Treatment of advanced ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1990 |
Intracavitary chemotherapy.
Topics: Absorption; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic | 1985 |
Intracavitary chemotherapy.
Topics: Absorption; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic | 1985 |
[Raynaud's phenomenon and finger necrosis after treatment of ovarian seminoma with bleomycin, vinblastine and 5-fluorouracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dysgerminoma; Female; Fingers; Flu | 1987 |
[Raynaud's phenomenon and finger necrosis after treatment of ovarian seminoma with bleomycin, vinblastine and 5-fluorouracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dysgerminoma; Female; Fingers; Flu | 1987 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
Chemotherapy in advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Cystadenocarcinoma; Cystadeno | 1973 |
Chemotherapy in advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Cystadenocarcinoma; Cystadeno | 1973 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
Current cancer chemotherapy in obstetrics and gynecology.
Topics: Alkaloids; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Blood Cell Count; Bone Marrow; | 1971 |
Current cancer chemotherapy in obstetrics and gynecology.
Topics: Alkaloids; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Blood Cell Count; Bone Marrow; | 1971 |
[Cytostatics for improvement of clinical tumor surgery].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Female; Fluorouracil; Gastrointestinal | 1973 |
[Cytostatics for improvement of clinical tumor surgery].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Female; Fluorouracil; Gastrointestinal | 1973 |
Chemotherapy of ovarian cancer with melphalan.
Topics: Adenocarcinoma; Ascites; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intr | 1968 |
Chemotherapy of ovarian cancer with melphalan.
Topics: Adenocarcinoma; Ascites; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intr | 1968 |
[Current status of chemotherapy of malignant tumors of the ovaries].
Topics: Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; | 1968 |
[Current status of chemotherapy of malignant tumors of the ovaries].
Topics: Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; | 1968 |
102 trials available for fluorouracil and Ovarian Neoplasms
| Article | Year |
|---|---|
Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 2008 |
Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 2008 |
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm | 2009 |
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm | 2009 |
A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2009 |
A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2009 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; | 2009 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; | 2009 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
[The modern organ- and function-sparing surgical treatment in oncology].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
[The modern organ- and function-sparing surgical treatment in oncology].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitab | 2003 |
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitab | 2003 |
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm | 2004 |
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm | 2004 |
Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progression; Fe | 2004 |
Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progression; Fe | 2004 |
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response R | 2004 |
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response R | 2004 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2005 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2005 |
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecita | 2006 |
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecita | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cohort Studi | 2008 |
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cohort Studi | 2008 |
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
[Treatment of advanced ovarian cancer as an interdisciplinary task: surgery, histopathology, radiotherapy, and chemotherapy].
Topics: Adenocarcinoma, Mucinous; Bleomycin; Bone and Bones; Carcinoma; Chlorambucil; Cyclophosphamide; Doxo | 1983 |
[Treatment of advanced ovarian cancer as an interdisciplinary task: surgery, histopathology, radiotherapy, and chemotherapy].
Topics: Adenocarcinoma, Mucinous; Bleomycin; Bone and Bones; Carcinoma; Chlorambucil; Cyclophosphamide; Doxo | 1983 |
Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Clinical Trial | 1981 |
Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Clinical Trial | 1981 |
A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical | 1984 |
A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical | 1984 |
[Clinical trial of carmofur (HCFU) in the treatment of malignant ovarian cancer--The first report: combination therapy with endoxan, mitomycin C, and toyomycin].
Topics: Adult; Aged; Antineoplastic Agents; Chromomycin A3; Clinical Trials as Topic; Cyclophosphamide; Drug | 1983 |
[Clinical trial of carmofur (HCFU) in the treatment of malignant ovarian cancer--The first report: combination therapy with endoxan, mitomycin C, and toyomycin].
Topics: Adult; Aged; Antineoplastic Agents; Chromomycin A3; Clinical Trials as Topic; Cyclophosphamide; Drug | 1983 |
Combination chemotherapy and immune capacity in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1984 |
Combination chemotherapy and immune capacity in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1984 |
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
Radiotherapeutic management of ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1984 |
[Clinical trial of cisplatin in the treatment of ovarian carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cystadenocarcino | 1982 |
[Clinical trial of cisplatin in the treatment of ovarian carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cystadenocarcino | 1982 |
Intensified nutrition as an adjunct to cytotoxic chemotherapy in gynaecological cancer patients.
Topics: Antineoplastic Agents; Body Weight; Cisplatin; Cyclophosphamide; Cystadenocarcinoma; Doxorubicin; Dr | 1982 |
Intensified nutrition as an adjunct to cytotoxic chemotherapy in gynaecological cancer patients.
Topics: Antineoplastic Agents; Body Weight; Cisplatin; Cyclophosphamide; Cystadenocarcinoma; Doxorubicin; Dr | 1982 |
[Chemotherapy of ovarian carcinoma].
Topics: Adult; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1982 |
[Chemotherapy of ovarian carcinoma].
Topics: Adult; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1982 |
Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; | 1981 |
Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; | 1981 |
Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma; Clinical Trials as Topic; Drug Administration | 1980 |
Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma; Clinical Trials as Topic; Drug Administration | 1980 |
A controlled clinical trial in advanced ovarian cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combin | 1982 |
A controlled clinical trial in advanced ovarian cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combin | 1982 |
Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin.
Topics: Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Erythrocyte Count; Female; Fluorouracil; | 1980 |
Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin.
Topics: Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Erythrocyte Count; Female; Fluorouracil; | 1980 |
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].
Topics: Adenocarcinoma; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxypr | 1980 |
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].
Topics: Adenocarcinoma; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxypr | 1980 |
High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Resist | 1995 |
High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Drug Resist | 1995 |
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1995 |
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1995 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Middle Aged; Mit | 1994 |
Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Middle Aged; Mit | 1994 |
Glucose effects in an ovarian cancer protocol of exceptional activity.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine | 1993 |
Glucose effects in an ovarian cancer protocol of exceptional activity.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine | 1993 |
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; CA-125 Antigen; Drug Therapy, Combination; Female; F | 1995 |
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; CA-125 Antigen; Drug Therapy, Combination; Female; F | 1995 |
[Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report].
Topics: Adenocarcinoma; Adult; Aged; Animals; Catheterization; Endometrial Neoplasms; Female; Fluorouracil; | 1995 |
[Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report].
Topics: Adenocarcinoma; Adult; Aged; Animals; Catheterization; Endometrial Neoplasms; Female; Fluorouracil; | 1995 |
[Home chemotherapy for peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubi | 1994 |
[Home chemotherapy for peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubi | 1994 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Resistance; | 1995 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Resistance; | 1995 |
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circadian Rhythm; Cis | 1994 |
Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circadian Rhythm; Cis | 1994 |
Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisp | 1994 |
Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisp | 1994 |
Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Mid | 1994 |
Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Mid | 1994 |
Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons | 1994 |
Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons | 1994 |
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1993 |
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1993 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1996 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1996 |
[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
Topics: Adult; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Drug | 1997 |
[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
Topics: Adult; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Drug | 1997 |
Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1999 |
Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1999 |
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2000 |
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2000 |
Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Epiru | 2001 |
Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Epiru | 2001 |
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Administrati | 1978 |
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Administrati | 1978 |
Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
Topics: Altretamine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1979 |
Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
Topics: Altretamine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1979 |
Histologic grade in advanced ovarian cancer.
Topics: Altretamine; Cell Differentiation; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil | 1979 |
Histologic grade in advanced ovarian cancer.
Topics: Altretamine; Cell Differentiation; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil | 1979 |
Advances in the staging and treatment of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cyclophos | 1977 |
Advances in the staging and treatment of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cyclophos | 1977 |
Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer
Topics: Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, | 1979 |
Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer
Topics: Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, | 1979 |
Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
Topics: Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1979 |
Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
Topics: Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1979 |
Second trial drugs in ovarian cancer.
Topics: Altretamine; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Female; Fluorou | 1977 |
Second trial drugs in ovarian cancer.
Topics: Altretamine; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Female; Fluorou | 1977 |
Ovarian cancer: use of multiple modality programs involving surgery, radiation therapy and chemotherapy.
Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Dactinomycin; Doxoru | 1977 |
Ovarian cancer: use of multiple modality programs involving surgery, radiation therapy and chemotherapy.
Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Dactinomycin; Doxoru | 1977 |
Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Topics: Altretamine; Bone Marrow; Clinical Trials as Topic; Digestive System; Drug Evaluation; Drug Therapy, | 1977 |
Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Topics: Altretamine; Bone Marrow; Clinical Trials as Topic; Digestive System; Drug Evaluation; Drug Therapy, | 1977 |
Chemotherapy in ovarian carcinoma recurrent after radiation therapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorourac | 1978 |
Chemotherapy in ovarian carcinoma recurrent after radiation therapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorourac | 1978 |
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin | 1975 |
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin | 1975 |
Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary.
Topics: Adult; Altretamine; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1975 |
Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary.
Topics: Adult; Altretamine; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1975 |
Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.
Topics: Adenocarcinoma; Alkylating Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug Therapy, Combi | 1975 |
Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.
Topics: Adenocarcinoma; Alkylating Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug Therapy, Combi | 1975 |
Single agent vs combination chemotherapy in the treatment of ovarian cancer.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorourac | 1977 |
Single agent vs combination chemotherapy in the treatment of ovarian cancer.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorourac | 1977 |
[Use of ftorafur for the treatment of 3d-4th stage].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Femal | 1975 |
[Use of ftorafur for the treatment of 3d-4th stage].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Femal | 1975 |
Advances in chemotherapy for gynecologic cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug | 1975 |
Advances in chemotherapy for gynecologic cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug | 1975 |
Report on treatment of cancer of the ovary.
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Ovarian Neoplasms; Prognosis; Radiotherapy Dosage; V | 1976 |
Report on treatment of cancer of the ovary.
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Ovarian Neoplasms; Prognosis; Radiotherapy Dosage; V | 1976 |
5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans | 1992 |
5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans | 1992 |
Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study.
Topics: Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Ovarian N | 1992 |
Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study.
Topics: Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Ovarian N | 1992 |
Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Flu | 1992 |
Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Flu | 1992 |
Intermittent intensive combination chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (cyclic PAC chemotherapy) for ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Admin | 1992 |
Intermittent intensive combination chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (cyclic PAC chemotherapy) for ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Admin | 1992 |
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1991 |
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1991 |
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1991 |
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1991 |
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1991 |
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1991 |
[Evaluation of UFT administration in patients with ovarian cancer who had no evidence of disease after the initial therapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1990 |
[Evaluation of UFT administration in patients with ovarian cancer who had no evidence of disease after the initial therapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1990 |
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1990 |
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1990 |
A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1990 |
A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
[Studies of second-look operations (SLO) in ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphami | 1989 |
[Studies of second-look operations (SLO) in ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphami | 1989 |
[Use of cytostatics deposited in cellulose acetate microspheres in the treatment of ovarian cancer].
Topics: Cellulose; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Combinations; Female; Fluor | 1989 |
[Use of cytostatics deposited in cellulose acetate microspheres in the treatment of ovarian cancer].
Topics: Cellulose; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Combinations; Female; Fluor | 1989 |
Complete remission at laparotomy: still a gold standard in ovarian cancer?
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
Complete remission at laparotomy: still a gold standard in ovarian cancer?
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
Continuous infusion fluoropyrimidines as salvage therapy for patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Mi | 1988 |
Continuous infusion fluoropyrimidines as salvage therapy for patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Mi | 1988 |
Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin | 1986 |
Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin | 1986 |
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1986 |
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1986 |
[Intra-arterial chemotherapy in advanced ovarian cancer. 2. Technic, results, complications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1987 |
[Intra-arterial chemotherapy in advanced ovarian cancer. 2. Technic, results, complications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1987 |
[Intra-arterial chemotherapy in advanced ovarian cancer. 1. Study conditions and prognostic factors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Th | 1987 |
[Intra-arterial chemotherapy in advanced ovarian cancer. 1. Study conditions and prognostic factors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Th | 1987 |
[Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1987 |
[Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1987 |
[The effect of immunochemotherapy with PSK in malignant tumors of the female reproductive organs].
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosp | 1986 |
[The effect of immunochemotherapy with PSK in malignant tumors of the female reproductive organs].
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosp | 1986 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
[Intra-arterial chemotherapy in advanced ovarian cancers. 2. Therapeutic results in relation to prognostic factors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; | 1987 |
[Intra-arterial chemotherapy in advanced ovarian cancers. 2. Therapeutic results in relation to prognostic factors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; | 1987 |
[Postoperative radio- and/or chemotherapy in ovarian stage III cancers. Results of a prospective randomized study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials | 1985 |
[Postoperative radio- and/or chemotherapy in ovarian stage III cancers. Results of a prospective randomized study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials | 1985 |
A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Tria | 1985 |
A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Tria | 1985 |
A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp | 1985 |
A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp | 1985 |
The case for combination chemotherapy in the treatment of advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1985 |
The case for combination chemotherapy in the treatment of advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1985 |
[Results of the Hamburg ovarian blastoma study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
[Results of the Hamburg ovarian blastoma study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: clinical trials.
Topics: Antineoplastic Agents; Blood Platelets; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1972 |
Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: clinical trials.
Topics: Antineoplastic Agents; Blood Platelets; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1972 |
[Treatment of advanced inoperable carcinoma of the ovaries (author's transl)].
Topics: Castration; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoroura | 1973 |
[Treatment of advanced inoperable carcinoma of the ovaries (author's transl)].
Topics: Castration; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoroura | 1973 |
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug | 1974 |
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug | 1974 |
370 other studies available for fluorouracil and Ovarian Neoplasms
| Article | Year |
|---|---|
Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase.
Topics: Acetanilides; Antineoplastic Agents; Cisplatin; Crystallography, X-Ray; Drug Screening Assays, Antit | 2012 |
Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase.
Topics: Acetanilides; Antineoplastic Agents; Cisplatin; Crystallography, X-Ray; Drug Screening Assays, Antit | 2012 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Fe | 2012 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Fe | 2012 |
Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.
Topics: Cell Division; Cell Line, Tumor; Circular Dichroism; Crystallography; Female; Humans; Molecular Dyna | 2014 |
Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.
Topics: Cell Division; Cell Line, Tumor; Circular Dichroism; Crystallography; Female; Humans; Molecular Dyna | 2014 |
Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells.
Topics: Cell Proliferation; Enzyme Inhibitors; Female; Fluorescence; Humans; Microscopy, Confocal; Molecular | 2014 |
Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells.
Topics: Cell Proliferation; Enzyme Inhibitors; Female; Fluorescence; Humans; Microscopy, Confocal; Molecular | 2014 |
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
Topics: Antineoplastic Agents; Cell Line, Tumor; Circular Dichroism; Enzyme Inhibitors; Female; Humans; Mole | 2018 |
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
Topics: Antineoplastic Agents; Cell Line, Tumor; Circular Dichroism; Enzyme Inhibitors; Female; Humans; Mole | 2018 |
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems | 2021 |
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems | 2021 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.
Topics: Animals; Binding Sites; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Ovarian Neoplasms; Th | 2022 |
Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.
Topics: Female; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; NK Cell Lectin-Like Receptor S | 2023 |
Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.
Topics: Female; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; NK Cell Lectin-Like Receptor S | 2023 |
In Vitro Employment of Recombinant Taenia solium Calreticulin as a Novel Strategy Against Breast and Ovarian Cancer Stem-like Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calreticulin; Cell Prolif | 2020 |
In Vitro Employment of Recombinant Taenia solium Calreticulin as a Novel Strategy Against Breast and Ovarian Cancer Stem-like Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calreticulin; Cell Prolif | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2020 |
Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expr | 2020 |
Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expr | 2020 |
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Ther | 2020 |
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Ther | 2020 |
Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
Topics: Adenoviridae; Aged; Bleomycin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Fatal Outcome; | 2020 |
Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
Topics: Adenoviridae; Aged; Bleomycin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Fatal Outcome; | 2020 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
[Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells].
Topics: 3' Untranslated Regions; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Female; Fl | 2017 |
[Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells].
Topics: 3' Untranslated Regions; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Female; Fl | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Corilagin from longan seed: Identification, quantification, and synergistic cytotoxicity on SKOv3ip and hey cells with ginsenoside Rh2 and 5-fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Therapy, Combination; Female; Fluorouracil; Free Radic | 2018 |
Corilagin from longan seed: Identification, quantification, and synergistic cytotoxicity on SKOv3ip and hey cells with ginsenoside Rh2 and 5-fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Therapy, Combination; Female; Fluorouracil; Free Radic | 2018 |
The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2018 |
The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2018 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Fa | 2018 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Fa | 2018 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
New findings on the antiproliferative activity of the silver(I) complex with 5-fluorouracil against human multi-resistant NCI/ADR-RES ovarian tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; D | 2019 |
New findings on the antiproliferative activity of the silver(I) complex with 5-fluorouracil against human multi-resistant NCI/ADR-RES ovarian tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; D | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2019 |
Uracil mustard and 5-fluorouracil combination chemotherapy: a historic record.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Flu | 2013 |
Uracil mustard and 5-fluorouracil combination chemotherapy: a historic record.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Flu | 2013 |
[Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease | 2013 |
[Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease | 2013 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycy | 2013 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycy | 2013 |
Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinogenesis; Carcinoma, Ovarian Epithelia | 2014 |
Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinogenesis; Carcinoma, Ovarian Epithelia | 2014 |
Combination of therapy with 5-fluorouracil and cisplatin with electroporation in human ovarian carcinoma model in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Survival; Cisplat | 2014 |
Combination of therapy with 5-fluorouracil and cisplatin with electroporation in human ovarian carcinoma model in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Survival; Cisplat | 2014 |
Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette | 2015 |
Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette | 2015 |
Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Blotting, Western; Carcin | 2015 |
Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Blotting, Western; Carcin | 2015 |
[Individualized therapy of synchronous ovarian and colon cancers with lymph].
Topics: Abdominal Pain; Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; | 2015 |
[Individualized therapy of synchronous ovarian and colon cancers with lymph].
Topics: Abdominal Pain; Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; | 2015 |
Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
Topics: Active Transport, Cell Nucleus; Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2015 |
Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
Topics: Active Transport, Cell Nucleus; Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2015 |
Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2015 |
Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2015 |
Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Female; Fluorouracil; Humans; In | 2015 |
Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Female; Fluorouracil; Humans; In | 2015 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2016 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2016 |
Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinogenesis; Cell Line, Tumor; Cell Prolife | 2016 |
Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinogenesis; Cell Line, Tumor; Cell Prolife | 2016 |
Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Ca | 2016 |
Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Ca | 2016 |
Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.
Topics: Antimetabolites, Antineoplastic; Cell Nucleus; Cell Survival; DNA Glycosylases; DNA Repair; DNA Repl | 2016 |
Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.
Topics: Antimetabolites, Antineoplastic; Cell Nucleus; Cell Survival; DNA Glycosylases; DNA Repair; DNA Repl | 2016 |
Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G₂ Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G2 Phase; Humans; MAP Kinase S | 2017 |
Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G₂ Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G2 Phase; Humans; MAP Kinase S | 2017 |
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deo | 2016 |
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deo | 2016 |
[Improve the chemosensitivity of resistant ovarian cancer cell by small RNA interference].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Doxorubici | 2008 |
[Improve the chemosensitivity of resistant ovarian cancer cell by small RNA interference].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Doxorubici | 2008 |
S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western | 2009 |
Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western | 2009 |
Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2009 |
Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2009 |
[Ovarian metastasis of breast cancer: a case report. Role of cytoreductive surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobu | 2009 |
[Ovarian metastasis of breast cancer: a case report. Role of cytoreductive surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobu | 2009 |
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Inf | 2009 |
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Inf | 2009 |
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neopla | 2009 |
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neopla | 2009 |
[A case of simultaneous bilateral metastatic ovarian tumor of colon cancer followed by FOLFOX4 Regimen and oral tegafur/uracil+oral leucovorin after R0 operation].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colectomy; C | 2009 |
[A case of simultaneous bilateral metastatic ovarian tumor of colon cancer followed by FOLFOX4 Regimen and oral tegafur/uracil+oral leucovorin after R0 operation].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colectomy; C | 2009 |
Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman.
Topics: Abdomen, Acute; Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Bio | 2010 |
Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman.
Topics: Abdomen, Acute; Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Bio | 2010 |
[Ovarian metastasis after complete response of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
[Ovarian metastasis after complete response of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Mucinous adenocarcinoma of the ovary.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cystadenocarcinoma, M | 2010 |
Mucinous adenocarcinoma of the ovary.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cystadenocarcinoma, M | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; | 2010 |
Involvement of ARLTS1 in chemotherapy and apoptosis in ovarian cancer cell line.
Topics: ADP-Ribosylation Factors; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; | 2011 |
Involvement of ARLTS1 in chemotherapy and apoptosis in ovarian cancer cell line.
Topics: ADP-Ribosylation Factors; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; | 2011 |
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
[A case report of primary adenocarcinoma of small intestine].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
[A case report of primary adenocarcinoma of small intestine].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Alendronate; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; | 2012 |
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Alendronate; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; | 2012 |
Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; | 2011 |
Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; | 2011 |
[A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deox | 2011 |
[A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deox | 2011 |
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.
Topics: Amino Acid Sequence; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cisplatin; Crystallography | 2011 |
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.
Topics: Amino Acid Sequence; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cisplatin; Crystallography | 2011 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA T | 2011 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA T | 2011 |
[A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens].
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Re | 2011 |
[A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens].
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Re | 2011 |
The value of palliative gastrectomy in gastric cancer with distant metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2012 |
The value of palliative gastrectomy in gastric cancer with distant metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2012 |
Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumo | 2012 |
Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumo | 2012 |
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bl | 2012 |
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bl | 2012 |
Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk.
Topics: Biomarkers, Tumor; Case-Control Studies; Cohort Studies; Dietary Supplements; Eating; Feeding Behavi | 2012 |
Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk.
Topics: Biomarkers, Tumor; Case-Control Studies; Cohort Studies; Dietary Supplements; Eating; Feeding Behavi | 2012 |
[A case of advanced colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fatal Outcome; Female; Fluorourac | 2012 |
[A case of advanced colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fatal Outcome; Female; Fluorourac | 2012 |
The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary | 2013 |
The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary | 2013 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil | 2013 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil | 2013 |
Correlation between cell survival, clonogenic activity and micronuclei induction in DMBA-OC-1R cells treated with immunospecific albumin microspheres containing cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell | 2002 |
Correlation between cell survival, clonogenic activity and micronuclei induction in DMBA-OC-1R cells treated with immunospecific albumin microspheres containing cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell | 2002 |
Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female; Fluor | 2002 |
Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female; Fluor | 2002 |
[An evaluation of adenosine triphosphate bioluminescence assay for tumor in vitro chemosensitivity testing].
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Screening Assay | 2000 |
[An evaluation of adenosine triphosphate bioluminescence assay for tumor in vitro chemosensitivity testing].
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Screening Assay | 2000 |
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Adult; Alopecia; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Adult; Alopecia; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2003 |
[Comparison between apoptosis cells count and ATP-bioluminescence assay in ovarian cancer chemosensitivity testing in vitro].
Topics: Antineoplastic Agents; Apoptosis; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouraci | 2002 |
[Comparison between apoptosis cells count and ATP-bioluminescence assay in ovarian cancer chemosensitivity testing in vitro].
Topics: Antineoplastic Agents; Apoptosis; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouraci | 2002 |
[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cisplatin; Deoxycy | 2003 |
[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cisplatin; Deoxycy | 2003 |
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Aziridines; Blotting, Western; Caspases; D | 2003 |
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Aziridines; Blotting, Western; Caspases; D | 2003 |
METHODOLOGY OF PRELIMINARY CHEMOTHERAPEUTIC TRIALS IN PATIENTS WITH MALIGNANT SOLID TUMORS.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Cyclophosp | 1963 |
METHODOLOGY OF PRELIMINARY CHEMOTHERAPEUTIC TRIALS IN PATIENTS WITH MALIGNANT SOLID TUMORS.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Cyclophosp | 1963 |
EFFECTS OF IONIZING IRRADIATION AND CHEMOTHERAPEUTIC AGENTS ON HUMAN CHROMOSOMES.
Topics: Antineoplastic Agents; Biomedical Research; Chlorambucil; Choriocarcinoma; Chromosome Aberrations; C | 1964 |
EFFECTS OF IONIZING IRRADIATION AND CHEMOTHERAPEUTIC AGENTS ON HUMAN CHROMOSOMES.
Topics: Antineoplastic Agents; Biomedical Research; Chlorambucil; Choriocarcinoma; Chromosome Aberrations; C | 1964 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
[CHEMOTHERAPY IN TREATMENT OF CARCINOMA OF THE OVARY].
Topics: Antineoplastic Agents; Aziridines; Cyclophosphamide; Drug Therapy; Female; Fluorouracil; Humans; Mit | 1964 |
[CHEMOTHERAPY IN TREATMENT OF CARCINOMA OF THE OVARY].
Topics: Antineoplastic Agents; Aziridines; Cyclophosphamide; Drug Therapy; Female; Fluorouracil; Humans; Mit | 1964 |
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 2003 |
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 2003 |
Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as | 2003 |
Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as | 2003 |
[A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Cystadenocarcinoma, Serous | 2003 |
[A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Cystadenocarcinoma, Serous | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinom | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinom | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; | 2003 |
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Flu | 2004 |
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Flu | 2004 |
Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Div | 2004 |
Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Div | 2004 |
The HPV16 E6/E7 oncogene sensitizes human ovarian surface epithelial cells to low-dose but not high-dose 5-FU and 5-FUdR.
Topics: Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Epithelial Cells; Female; Floxuridine | 2004 |
The HPV16 E6/E7 oncogene sensitizes human ovarian surface epithelial cells to low-dose but not high-dose 5-FU and 5-FUdR.
Topics: Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Epithelial Cells; Female; Floxuridine | 2004 |
Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
Topics: Adenoviridae; Artificial Gene Fusion; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosi | 2004 |
Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
Topics: Adenoviridae; Artificial Gene Fusion; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosi | 2004 |
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; C | 2004 |
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; C | 2004 |
[Gene therapy for ovarian cancer by adenovirus-mediated transduction of cytosine deaminase gene in vitro].
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cloning, Molecular; Cytosine Deamin | 2003 |
[Gene therapy for ovarian cancer by adenovirus-mediated transduction of cytosine deaminase gene in vitro].
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cloning, Molecular; Cytosine Deamin | 2003 |
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].
Topics: 5'-Nucleotidase; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineo | 2004 |
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].
Topics: 5'-Nucleotidase; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineo | 2004 |
CA-125 criteria for response evaluation in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Female; Fluorouracil; Humans; Leucov | 2005 |
CA-125 criteria for response evaluation in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Female; Fluorouracil; Humans; Leucov | 2005 |
Intraperitoneal chemotherapy in ovarian carcinoma with the combination of carboplatin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluorouracil; Humans; Infusions | 1989 |
Intraperitoneal chemotherapy in ovarian carcinoma with the combination of carboplatin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluorouracil; Humans; Infusions | 1989 |
Oxaliplatin-related acute myelogenous leukemia.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2006 |
Oxaliplatin-related acute myelogenous leukemia.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2006 |
Not in the BNF.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Emergency Service, Hospital; Fat | 2006 |
Not in the BNF.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Emergency Service, Hospital; Fat | 2006 |
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2006 |
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2006 |
[Treatment of malignant ovarian tumours in Georgia in 1990-2000].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Cyclophosphami | 2006 |
[Treatment of malignant ovarian tumours in Georgia in 1990-2000].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Cyclophosphami | 2006 |
[A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2006 |
[A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2006 |
Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter.
Topics: Adenoviridae; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cy | 2007 |
Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter.
Topics: Adenoviridae; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cy | 2007 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Ovarian and parovarian tumors in infants and children.
Topics: Adenocarcinoma; Adolescent; Child; Child, Preschool; Dysgerminoma; Female; Fluorouracil; Histocytoch | 1967 |
Ovarian and parovarian tumors in infants and children.
Topics: Adenocarcinoma; Adolescent; Child; Child, Preschool; Dysgerminoma; Female; Fluorouracil; Histocytoch | 1967 |
[Simultaneous radio-chemotherapy of advanced epithelial ovarian cancer--results after three years (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Chlorambucil; Doxorubicin; Drug Therapy, Combination; | 1981 |
[Simultaneous radio-chemotherapy of advanced epithelial ovarian cancer--results after three years (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Chlorambucil; Doxorubicin; Drug Therapy, Combination; | 1981 |
Effects of cytostatic drugs on the transmembrane potential and surface charge of cultured cells.
Topics: Antineoplastic Agents; Bleomycin; Cell Line; Female; Fluorouracil; HeLa Cells; Humans; Ion Channels; | 1981 |
Effects of cytostatic drugs on the transmembrane potential and surface charge of cultured cells.
Topics: Antineoplastic Agents; Bleomycin; Cell Line; Female; Fluorouracil; HeLa Cells; Humans; Ion Channels; | 1981 |
Endodermal sinus tumor of the ovary: the M. D. Anderson experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Castration; Child; Cis | 1983 |
Endodermal sinus tumor of the ovary: the M. D. Anderson experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Castration; Child; Cis | 1983 |
Serial serum determination on alpha-fetoprotein as a marker of the effect of postoperative chemotherapy in ovarian endodermal sinus tumor.
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carbazilquino | 1984 |
Serial serum determination on alpha-fetoprotein as a marker of the effect of postoperative chemotherapy in ovarian endodermal sinus tumor.
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carbazilquino | 1984 |
[Platin-containing cytostatic combinations in the therapy of advanced gynecologic carcinomas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cisplatin; Cyclop | 1984 |
[Platin-containing cytostatic combinations in the therapy of advanced gynecologic carcinomas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cisplatin; Cyclop | 1984 |
Peritoneo-cystic shunt for malignant ascites.
Topics: Ascites; Aspartic Acid; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Ovaria | 1984 |
Peritoneo-cystic shunt for malignant ascites.
Topics: Ascites; Aspartic Acid; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Ovaria | 1984 |
Intraarterial infusion chemotherapy in the treatment of liver metastases from ovarian cancer.
Topics: Antineoplastic Agents; Cystadenocarcinoma; Doxorubicin; Drug Therapy, Combination; Endometriosis; Fe | 1981 |
Intraarterial infusion chemotherapy in the treatment of liver metastases from ovarian cancer.
Topics: Antineoplastic Agents; Cystadenocarcinoma; Doxorubicin; Drug Therapy, Combination; Endometriosis; Fe | 1981 |
Intra-arterial infusion in tumors of the pelvis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
Intra-arterial infusion in tumors of the pelvis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
The treatment of 48 patients affected by ovarian carcinoma at stages III and IV F.I.G.O.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Cyclophosphamide; Cystadenocarcinoma; Female; Fluorouracil; H | 1981 |
The treatment of 48 patients affected by ovarian carcinoma at stages III and IV F.I.G.O.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Cyclophosphamide; Cystadenocarcinoma; Female; Fluorouracil; H | 1981 |
[Treatment of advanced ovarian cancer].
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo | 1984 |
[Treatment of advanced ovarian cancer].
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo | 1984 |
[Experiences with Volm's short-term tumor test in the primary treatment of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cells, Cultured; Cisplatin | 1984 |
[Experiences with Volm's short-term tumor test in the primary treatment of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cells, Cultured; Cisplatin | 1984 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
[Nonspecific cell-mediated immunity of gynecologic cancer patients and related effects of chemotherapy and immunotherapy].
Topics: Female; Fluorouracil; Humans; Immunity, Cellular; Leukocyte Count; Mitomycin; Mitomycins; Ovarian Ne | 1983 |
[Nonspecific cell-mediated immunity of gynecologic cancer patients and related effects of chemotherapy and immunotherapy].
Topics: Female; Fluorouracil; Humans; Immunity, Cellular; Leukocyte Count; Mitomycin; Mitomycins; Ovarian Ne | 1983 |
Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Cyclopho | 1983 |
Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Cyclopho | 1983 |
[Chemotherapy of epithelial ovarian carcinoma].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chlorambucil; Cisplatin; Cyc | 1983 |
[Chemotherapy of epithelial ovarian carcinoma].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chlorambucil; Cisplatin; Cyc | 1983 |
[Long-term maintenance chemotherapy for pseudomyxoma peritonei of ovarian origin].
Topics: Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged; Neoplasm Seeding; O | 1984 |
[Long-term maintenance chemotherapy for pseudomyxoma peritonei of ovarian origin].
Topics: Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged; Neoplasm Seeding; O | 1984 |
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra | 1984 |
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra | 1984 |
Repetitive debulking surgery as adjuvant to chemotherapy in advanced epithelial ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1984 |
Repetitive debulking surgery as adjuvant to chemotherapy in advanced epithelial ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1984 |
[Chemotherapy in advanced forms of carcinoma of the ovary].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1984 |
[Chemotherapy in advanced forms of carcinoma of the ovary].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1984 |
The chemotherapy of granulosa cell tumors of the ovary: experience of the Wisconsin Clinical Cancer Center.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha | 1984 |
The chemotherapy of granulosa cell tumors of the ovary: experience of the Wisconsin Clinical Cancer Center.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha | 1984 |
Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer.
Topics: Abdomen; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Ovarian Neopla | 1984 |
Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer.
Topics: Abdomen; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Ovarian Neopla | 1984 |
Abnormal deoxyuridine suppression as a rapid predictor for antimetabolite chemosensitivity: correlation with in vitro tests of growth inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; Colony-Forming Units Assay; Deox | 1984 |
Abnormal deoxyuridine suppression as a rapid predictor for antimetabolite chemosensitivity: correlation with in vitro tests of growth inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; Colony-Forming Units Assay; Deox | 1984 |
Supraventricular tachycardia. A probable complication of platinum treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma; Dox | 1984 |
Supraventricular tachycardia. A probable complication of platinum treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma; Dox | 1984 |
New possibilities of cytostatic drug testing on patient tumor cells by flow cytometry.
Topics: Antineoplastic Agents; Ascitic Fluid; Cell Survival; Cells, Cultured; Cisplatin; Cyclophosphamide; D | 1984 |
New possibilities of cytostatic drug testing on patient tumor cells by flow cytometry.
Topics: Antineoplastic Agents; Ascitic Fluid; Cell Survival; Cells, Cultured; Cisplatin; Cyclophosphamide; D | 1984 |
Timed sequential chemotherapy following drug-induced kinetic recruitment in refractory ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cell Division; Doxorubicin; Female; | 1984 |
Timed sequential chemotherapy following drug-induced kinetic recruitment in refractory ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cell Division; Doxorubicin; Female; | 1984 |
Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorourac | 1984 |
Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorourac | 1984 |
Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1983 |
Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1983 |
[Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 1983 |
[Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 1983 |
[Ovarian carcinoma: surgery and polychemotherapy with cisplatin. Considerations on a clinical case].
Topics: Carcinoma; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Me | 1983 |
[Ovarian carcinoma: surgery and polychemotherapy with cisplatin. Considerations on a clinical case].
Topics: Carcinoma; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Me | 1983 |
[Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Evaluati | 1980 |
[Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Evaluati | 1980 |
[Endolymphatic polychemotherapy of ovarian cancer].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluor | 1981 |
[Endolymphatic polychemotherapy of ovarian cancer].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluor | 1981 |
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin | 1981 |
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin | 1981 |
In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.
Topics: Alkylating Agents; Antimetabolites, Antineoplastic; Cell Survival; Cells, Cultured; Dactinomycin; Dr | 1981 |
In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.
Topics: Alkylating Agents; Antimetabolites, Antineoplastic; Cell Survival; Cells, Cultured; Dactinomycin; Dr | 1981 |
Prospective study with HEXA-CAF combination in ovarian carcinoma.
Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouraci | 1981 |
Prospective study with HEXA-CAF combination in ovarian carcinoma.
Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouraci | 1981 |
[Long-term chemotherapy with FT-207 for ovarian cancer (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorourac | 1981 |
[Long-term chemotherapy with FT-207 for ovarian cancer (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorourac | 1981 |
FQC combination chemotherapy for primary malignant ovarian tumor.
Topics: Azirines; Carbazilquinone; Cytarabine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Ovar | 1982 |
FQC combination chemotherapy for primary malignant ovarian tumor.
Topics: Azirines; Carbazilquinone; Cytarabine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Ovar | 1982 |
Inhibition of galactosyltransferase by 5-fluorouracil.
Topics: Female; Fluorouracil; Galactosyltransferases; Humans; In Vitro Techniques; Lactose Synthase; Ovarian | 1982 |
Inhibition of galactosyltransferase by 5-fluorouracil.
Topics: Female; Fluorouracil; Galactosyltransferases; Humans; In Vitro Techniques; Lactose Synthase; Ovarian | 1982 |
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1982 |
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1982 |
[Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer].
Topics: Adenocarcinoma; Azirines; Carbazilquinone; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1982 |
[Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer].
Topics: Adenocarcinoma; Azirines; Carbazilquinone; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1982 |
[Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Drug Therapy, Combinatio | 1982 |
[Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Drug Therapy, Combinatio | 1982 |
[Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug T | 1982 |
[Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug T | 1982 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Human ovarian cancer colony formation: growth from malignant washings and pharmacologic applications.
Topics: Agar; Antineoplastic Agents; Ascitic Fluid; Cell Division; Cells, Cultured; Clone Cells; Doxorubicin | 1980 |
Human ovarian cancer colony formation: growth from malignant washings and pharmacologic applications.
Topics: Agar; Antineoplastic Agents; Ascitic Fluid; Cell Division; Cells, Cultured; Clone Cells; Doxorubicin | 1980 |
[Effect of 5-fluorouracil (5 Fu) on growth and morphology of human ovarian clear cell carcinoma transplanted into nude mice (author's transl)].
Topics: Adenocarcinoma; Adult; Animals; Female; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplanta | 1981 |
[Effect of 5-fluorouracil (5 Fu) on growth and morphology of human ovarian clear cell carcinoma transplanted into nude mice (author's transl)].
Topics: Adenocarcinoma; Adult; Animals; Female; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplanta | 1981 |
[Renal lesions after irradiation and chemotherapy with adriamycin, vincristin and 5-fluoro-uracil (author's transl)].
Topics: Acute Kidney Injury; Adult; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Ki | 1981 |
[Renal lesions after irradiation and chemotherapy with adriamycin, vincristin and 5-fluoro-uracil (author's transl)].
Topics: Acute Kidney Injury; Adult; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Ki | 1981 |
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.
Topics: Adult; Aged; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1980 |
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.
Topics: Adult; Aged; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1980 |
Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity.
Topics: Antineoplastic Agents; Cell Survival; Cytarabine; Dactinomycin; Doxorubicin; Drug Evaluation, Precli | 1980 |
Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity.
Topics: Antineoplastic Agents; Cell Survival; Cytarabine; Dactinomycin; Doxorubicin; Drug Evaluation, Precli | 1980 |
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Inje | 1980 |
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Inje | 1980 |
Alpha-fetoprotein in advanced epithelial ovarian cancer.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; F | 1993 |
Alpha-fetoprotein in advanced epithelial ovarian cancer.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; F | 1993 |
The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis.
Topics: Adult; Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone | 1995 |
The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis.
Topics: Adult; Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone | 1995 |
Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorouracil; Hum | 1995 |
Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorouracil; Hum | 1995 |
Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Fluor | 1994 |
Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Fluor | 1994 |
Long-term follow-up of patients with epithelial carcinoma of the ovary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Cytarabine; | 1994 |
Long-term follow-up of patients with epithelial carcinoma of the ovary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Cytarabine; | 1994 |
Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1994 |
Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1994 |
Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1994 |
Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1994 |
[Adjuvant chemotherapy in ovarian carcinoma. Preliminary results].
Topics: Adnexa Uteri; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bulgaria; Carcinoma; Chem | 1993 |
[Adjuvant chemotherapy in ovarian carcinoma. Preliminary results].
Topics: Adnexa Uteri; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bulgaria; Carcinoma; Chem | 1993 |
[A case of advanced gastric cancer surviving 3 years and 6 months after resection of Krukenberg's tumor].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplati | 1994 |
[A case of advanced gastric cancer surviving 3 years and 6 months after resection of Krukenberg's tumor].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplati | 1994 |
Carboquone combined with methotrexate and 5-fluorouracil for recurrent and advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Female; Fluorouracil; | 1993 |
Carboquone combined with methotrexate and 5-fluorouracil for recurrent and advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Female; Fluorouracil; | 1993 |
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance | 1993 |
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance | 1993 |
Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administratio | 1993 |
Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administratio | 1993 |
Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 1993 |
Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 1993 |
Second-look laparotomy in the management of patients after radical surgery for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 1993 |
Second-look laparotomy in the management of patients after radical surgery for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 1993 |
Pseudomyxoma peritonei: treatment with intraperitoneal 5-fluorouracil.
Topics: Adult; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; F | 1993 |
Pseudomyxoma peritonei: treatment with intraperitoneal 5-fluorouracil.
Topics: Adult; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; F | 1993 |
Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; CA-125 Antigen; Drug Therapy, Combination; | 1996 |
Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; CA-125 Antigen; Drug Therapy, Combination; | 1996 |
Hypertensive reactions associated with paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bloo | 1996 |
Hypertensive reactions associated with paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bloo | 1996 |
[Synergistic effects of tumor necrosis factor interferon-gamma and chemotherapeutic drugs on human ovarian cancer cell lines in vitro].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Division; Drug Synergism; Epirubic | 1995 |
[Synergistic effects of tumor necrosis factor interferon-gamma and chemotherapeutic drugs on human ovarian cancer cell lines in vitro].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Division; Drug Synergism; Epirubic | 1995 |
[Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells].
Topics: Antineoplastic Agents; Cisplatin; Cystadenocarcinoma, Serous; DNA, Antisense; DNA, Complementary; Dr | 1996 |
[Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells].
Topics: Antineoplastic Agents; Cisplatin; Cystadenocarcinoma, Serous; DNA, Antisense; DNA, Complementary; Dr | 1996 |
Meta-analyses of randomised trials: when the whole is more than just the sum of the parts.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin | 1996 |
Meta-analyses of randomised trials: when the whole is more than just the sum of the parts.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin | 1996 |
Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 1996 |
Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 1996 |
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic | 1996 |
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic | 1996 |
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Ce | 1997 |
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Ce | 1997 |
Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclobuta | 1997 |
Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclobuta | 1997 |
Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; ATP Binding Cassette | 1997 |
Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; ATP Binding Cassette | 1997 |
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Colonic Neo | 1997 |
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Colonic Neo | 1997 |
In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; beta-Cyclodex | 1998 |
In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; beta-Cyclodex | 1998 |
[Chemotherapy repeated injection via pelvic retroperitoneal cannulation].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Dogs; Endometrial Ne | 1997 |
[Chemotherapy repeated injection via pelvic retroperitoneal cannulation].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Dogs; Endometrial Ne | 1997 |
Anti-proliferative activity and mechanism of action of titanocene dichloride.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell D | 1998 |
Anti-proliferative activity and mechanism of action of titanocene dichloride.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell D | 1998 |
Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1998 |
Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1998 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
[Successful treatment of a patient with recurrent ovarian clear cell adenocarcinoma under combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.)].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2000 |
[Successful treatment of a patient with recurrent ovarian clear cell adenocarcinoma under combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.)].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2000 |
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcino | 1999 |
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcino | 1999 |
Ovarian-cancer results cause a stir at cancer conference.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cyclophosphamid | 2000 |
Ovarian-cancer results cause a stir at cancer conference.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cyclophosphamid | 2000 |
Colon carcinoma with synchronous ovarian metastasis--report and discussion of five cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2000 |
Colon carcinoma with synchronous ovarian metastasis--report and discussion of five cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2000 |
Heat shock protein expression in human tumours grown in severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Femal | 2000 |
Heat shock protein expression in human tumours grown in severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Femal | 2000 |
Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin | 2001 |
Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin | 2001 |
[Appendiceal mucinous carcinoma].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2000 |
[Appendiceal mucinous carcinoma].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2000 |
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cispla | 2000 |
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cispla | 2000 |
Assessment of the antitumour activity of targeted immunospecific albumin microspheres loaded with cisplatin and 5-fluorouracil: toxicity against a rodent ovarian carcinoma in vitro.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; | 2001 |
Assessment of the antitumour activity of targeted immunospecific albumin microspheres loaded with cisplatin and 5-fluorouracil: toxicity against a rodent ovarian carcinoma in vitro.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; | 2001 |
[Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Papillary; Female; Fl | 1999 |
[Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Papillary; Female; Fl | 1999 |
[The contrast between chemotherapy via pelvic retroperitoneal cannulation and intraperitoneal chemotherapy in gynecological malignancies cancers with lymph node metastases].
Topics: Antimetabolites, Antineoplastic; Endometrial Neoplasms; Female; Fluorouracil; Humans; Injections, In | 1999 |
[The contrast between chemotherapy via pelvic retroperitoneal cannulation and intraperitoneal chemotherapy in gynecological malignancies cancers with lymph node metastases].
Topics: Antimetabolites, Antineoplastic; Endometrial Neoplasms; Female; Fluorouracil; Humans; Injections, In | 1999 |
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Topics: Adenoviridae; Animals; Cytomegalovirus; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene | 2001 |
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Topics: Adenoviridae; Animals; Cytomegalovirus; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene | 2001 |
[Chemotherapy-associated myelosuppression in gynecological oncology].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemothe | 2001 |
[Chemotherapy-associated myelosuppression in gynecological oncology].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemothe | 2001 |
Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cytosol; Deoxycytidine; Dihydrouracil Dehydroge | 2002 |
Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cytosol; Deoxycytidine; Dihydrouracil Dehydroge | 2002 |
Allopurinol modulation of high-dose fluorouracil toxicity.
Topics: Administration, Oral; Allopurinol; Drug Antagonism; Drug Therapy, Combination; Female; Fluorouracil; | 1979 |
Allopurinol modulation of high-dose fluorouracil toxicity.
Topics: Administration, Oral; Allopurinol; Drug Antagonism; Drug Therapy, Combination; Female; Fluorouracil; | 1979 |
Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Doxorubicin; Drug Eva | 1979 |
Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Doxorubicin; Drug Eva | 1979 |
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.
Topics: Adult; Antineoplastic Agents; Ascitic Fluid; Contrast Media; Female; Fluorouracil; Humans; Injection | 1979 |
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.
Topics: Adult; Antineoplastic Agents; Ascitic Fluid; Contrast Media; Female; Fluorouracil; Humans; Injection | 1979 |
Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.
Topics: Antineoplastic Agents; Autoradiography; Breast Neoplasms; Cell Count; Cell Division; Culture Techniq | 1975 |
Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.
Topics: Antineoplastic Agents; Autoradiography; Breast Neoplasms; Cell Count; Cell Division; Culture Techniq | 1975 |
Heterologous growth of human ovarian cancer. A new in vivo testing system.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Humans; Injections, Intramuscular; Injections, Intrap | 1977 |
Heterologous growth of human ovarian cancer. A new in vivo testing system.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Humans; Injections, Intramuscular; Injections, Intrap | 1977 |
Acute leukemia after alkylating-agent therapy of ovarian cancer.
Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; | 1977 |
Acute leukemia after alkylating-agent therapy of ovarian cancer.
Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; | 1977 |
[Chemotherapy of the ovarian carcinoma (author's transl)].
Topics: Altretamine; Antineoplastic Agents; Chlorambucil; Cisplatin; Cyclophosphamide; Doxorubicin; Drug The | 1977 |
[Chemotherapy of the ovarian carcinoma (author's transl)].
Topics: Altretamine; Antineoplastic Agents; Chlorambucil; Cisplatin; Cyclophosphamide; Doxorubicin; Drug The | 1977 |
Current concepts in the management of ovarian cancer.
Topics: Adult; Aged; Altretamine; Castration; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil | 1978 |
Current concepts in the management of ovarian cancer.
Topics: Adult; Aged; Altretamine; Castration; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil | 1978 |
[Comparison of the results of single-drug and combination chemotherapy of advanced ovarian cancer after 1 year].
Topics: Antineoplastic Agents; Dactinomycin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1979 |
[Comparison of the results of single-drug and combination chemotherapy of advanced ovarian cancer after 1 year].
Topics: Antineoplastic Agents; Dactinomycin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1979 |
Transplantation of experimental ovarian tumors and their sensitivity to carcinostatics.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Granulosa Cell Tumor; Humans; Male; Mitomycins; Neopl | 1979 |
Transplantation of experimental ovarian tumors and their sensitivity to carcinostatics.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Granulosa Cell Tumor; Humans; Male; Mitomycins; Neopl | 1979 |
[Early results of polychemotherapy in advanced ovarian tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Carcinoma, Papillary; Cyclophosphamide; Cyst | 1979 |
[Early results of polychemotherapy in advanced ovarian tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Carcinoma, Papillary; Cyclophosphamide; Cyst | 1979 |
[Registration of cytostatic effects on cultured cells in vitro and their current significance for individualized chemotherapy of tumors in advanced ovarian carcinoma].
Topics: Acrylates; Antineoplastic Agents; Cells, Cultured; Cyclophosphamide; Female; Fluorouracil; Humans; I | 1977 |
[Registration of cytostatic effects on cultured cells in vitro and their current significance for individualized chemotherapy of tumors in advanced ovarian carcinoma].
Topics: Acrylates; Antineoplastic Agents; Cells, Cultured; Cyclophosphamide; Female; Fluorouracil; Humans; I | 1977 |
[Experience with chemotherapy in peritoneal carcinosis].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1977 |
[Experience with chemotherapy in peritoneal carcinosis].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1977 |
Chemotherapy of ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Fe | 1978 |
Chemotherapy of ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Fe | 1978 |
[Pseudomyxoma of the peritoneum (author's transl)].
Topics: Ascites; Cystadenoma; Female; Fluorouracil; Humans; Hydrazines; Methotrexate; Middle Aged; Myxoma; O | 1978 |
[Pseudomyxoma of the peritoneum (author's transl)].
Topics: Ascites; Cystadenoma; Female; Fluorouracil; Humans; Hydrazines; Methotrexate; Middle Aged; Myxoma; O | 1978 |
[The primary appendix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Appendiceal Neoplasms; Colostomy; Cyclophosphamide; Female; Fluorouraci | 1978 |
[The primary appendix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Appendiceal Neoplasms; Colostomy; Cyclophosphamide; Female; Fluorouraci | 1978 |
[Results of high-dosage attack treatment with cytostatics in mammary and ovarian cancer (author's transl)].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexat | 1978 |
[Results of high-dosage attack treatment with cytostatics in mammary and ovarian cancer (author's transl)].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexat | 1978 |
Malignant teratoma of the ovary: prognostic factors and treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Cyclophosphamide; Dactinomycin; Drug Therapy, Combi | 1978 |
Malignant teratoma of the ovary: prognostic factors and treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Cyclophosphamide; Dactinomycin; Drug Therapy, Combi | 1978 |
Fresh explant culture of human tumours in vitro and the assessment of sensitivity to cytotoxic chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Culture Techniques; Drug Evaluation, Preclini | 1975 |
Fresh explant culture of human tumours in vitro and the assessment of sensitivity to cytotoxic chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Culture Techniques; Drug Evaluation, Preclini | 1975 |
Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immune | 1975 |
Immunological overshoot phenomenon following cancer chemotherapy: significance in prognosis evaluation of solid tumors.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immune | 1975 |
[Endolymphatic polychemotherapy of cancer of the ovaries].
Topics: Adult; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1975 |
[Endolymphatic polychemotherapy of cancer of the ovaries].
Topics: Adult; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1975 |
[Ultrastructural changes in ovarian tumor cancer cells under the influence of preoperative chemotherapy].
Topics: Cell Nucleolus; Chromatin; Cystadenocarcinoma; Female; Fluorouracil; Humans; Mitochondria; Ovarian N | 1976 |
[Ultrastructural changes in ovarian tumor cancer cells under the influence of preoperative chemotherapy].
Topics: Cell Nucleolus; Chromatin; Cystadenocarcinoma; Female; Fluorouracil; Humans; Mitochondria; Ovarian N | 1976 |
Chemotherapy in advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combi | 1975 |
Chemotherapy in advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combi | 1975 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1977 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1977 |
Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.
Topics: Adult; Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1977 |
Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.
Topics: Adult; Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1977 |
5-FU infusion and cyclophosphamide in the treatment of advanced ovarian cancer.
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluor | 1977 |
5-FU infusion and cyclophosphamide in the treatment of advanced ovarian cancer.
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluor | 1977 |
[In vitro testing and clinical experience with 5-fluorouracil in gynaecologic cancer (author's transl)].
Topics: Adult; Aged; Culture Techniques; Drug Evaluation; Female; Fluorouracil; Genital Neoplasms, Female; H | 1976 |
[In vitro testing and clinical experience with 5-fluorouracil in gynaecologic cancer (author's transl)].
Topics: Adult; Aged; Culture Techniques; Drug Evaluation; Female; Fluorouracil; Genital Neoplasms, Female; H | 1976 |
[Cytostatic therapy of inoperable carcinomas].
Topics: Breast Neoplasms; Bronchial Neoplasms; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin | 1976 |
[Cytostatic therapy of inoperable carcinomas].
Topics: Breast Neoplasms; Bronchial Neoplasms; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin | 1976 |
[Five years treatment of advanced solid malignomas with a combination of four cytostatic drugs (author's transl)].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1976 |
[Five years treatment of advanced solid malignomas with a combination of four cytostatic drugs (author's transl)].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1976 |
Endodermal sinus tumor: a report of two sustained remissions treated postoperatively with a combination of actinomycin D, 5-fluorouracil, and cyclophosphamide.
Topics: Adolescent; Adult; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Endodermal sinus tumor: a report of two sustained remissions treated postoperatively with a combination of actinomycin D, 5-fluorouracil, and cyclophosphamide.
Topics: Adolescent; Adult; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy, and radiation therapy.
Topics: Adenocarcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Laparotomy; Melp | 1975 |
Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy, and radiation therapy.
Topics: Adenocarcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Laparotomy; Melp | 1975 |
[Cell cycle and carcinochemotherapy: reality or hope? (author's transl)].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cyclophosphamide; Drug Therapy, Combination; | 1975 |
[Cell cycle and carcinochemotherapy: reality or hope? (author's transl)].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cyclophosphamide; Drug Therapy, Combination; | 1975 |
[1st report on programmed chemotherapy of ovarian carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinoma; Cystadenoma; Drug Thera | 1975 |
[1st report on programmed chemotherapy of ovarian carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinoma; Cystadenoma; Drug Thera | 1975 |
Results of the Gynecologic Oncology Group trials on ovarian cancer: preliminary report.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorourac | 1975 |
Results of the Gynecologic Oncology Group trials on ovarian cancer: preliminary report.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorourac | 1975 |
[Improving the curative effect of chemotherapy on gynecological malignant tumor by catheterization of internal iliac artery].
Topics: Adult; Aged; Chemoembolization, Therapeutic; Choriocarcinoma; Cisplatin; Doxorubicin; Female; Fluoro | 1992 |
[Improving the curative effect of chemotherapy on gynecological malignant tumor by catheterization of internal iliac artery].
Topics: Adult; Aged; Chemoembolization, Therapeutic; Choriocarcinoma; Cisplatin; Doxorubicin; Female; Fluoro | 1992 |
[Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1992 |
[Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1992 |
5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedu | 1992 |
5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedu | 1992 |
[Intraperitoneal chemotherapy of metastatic ovarian cancer].
Topics: Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; | 1992 |
[Intraperitoneal chemotherapy of metastatic ovarian cancer].
Topics: Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; | 1992 |
Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated x-irradiation in vitro.
Topics: Cisplatin; Combined Modality Therapy; Cystadenocarcinoma; Drug Resistance; Female; Fluorouracil; Glu | 1992 |
Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated x-irradiation in vitro.
Topics: Cisplatin; Combined Modality Therapy; Cystadenocarcinoma; Drug Resistance; Female; Fluorouracil; Glu | 1992 |
Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance | 1992 |
Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance | 1992 |
Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Topics: Antineoplastic Agents; Catalase; Cell Division; Cell Line; Cell Survival; Cisplatin; DNA-Directed DN | 1992 |
Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Topics: Antineoplastic Agents; Catalase; Cell Division; Cell Line; Cell Survival; Cisplatin; DNA-Directed DN | 1992 |
[Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; | 1992 |
[Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; | 1992 |
Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin.
Topics: Adult; Carboplatin; Cisplatin; Drug Evaluation; Drug Resistance; Female; Fluorouracil; Humans; Infus | 1991 |
Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin.
Topics: Adult; Carboplatin; Cisplatin; Drug Evaluation; Drug Resistance; Female; Fluorouracil; Humans; Infus | 1991 |
[Polymer-drug complexes in the treatment of extensive ovarian cancer].
Topics: Adult; Cellulose; Cyclophosphamide; Cystadenocarcinoma; Doxorubicin; Evaluation Studies as Topic; Fe | 1991 |
[Polymer-drug complexes in the treatment of extensive ovarian cancer].
Topics: Adult; Cellulose; Cyclophosphamide; Cystadenocarcinoma; Doxorubicin; Evaluation Studies as Topic; Fe | 1991 |
[Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; | 1991 |
[Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; | 1991 |
[Investigation of 5-fluorouracil (5-FU) levels and pyrimidine nucleoside phosphorylase activities in the tissues from patients with uterine cervical and ovarian cancers after oral administration of 5'-DFUR].
Topics: Administration, Oral; Antineoplastic Agents; Female; Floxuridine; Fluorouracil; Humans; Lymph Nodes; | 1991 |
[Investigation of 5-fluorouracil (5-FU) levels and pyrimidine nucleoside phosphorylase activities in the tissues from patients with uterine cervical and ovarian cancers after oral administration of 5'-DFUR].
Topics: Administration, Oral; Antineoplastic Agents; Female; Floxuridine; Fluorouracil; Humans; Lymph Nodes; | 1991 |
Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cispl | 1991 |
Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cispl | 1991 |
[Intraperitoneal chemotherapy through implantable injection port in patients with advanced ovarian (or tubal) carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administra | 1991 |
[Intraperitoneal chemotherapy through implantable injection port in patients with advanced ovarian (or tubal) carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administra | 1991 |
[A case of granulosa cell tumor with unusual histologic features].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Combined Modality Therapy; Cy | 1991 |
[A case of granulosa cell tumor with unusual histologic features].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Combined Modality Therapy; Cy | 1991 |
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
Topics: Animals; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Female; | 1991 |
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
Topics: Animals; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Female; | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
Fist line chemotherapy in advanced ovarian cancer: a comparison of three therapeutic regimes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophos | 1990 |
Fist line chemotherapy in advanced ovarian cancer: a comparison of three therapeutic regimes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophos | 1990 |
Comparative study of combination chemotherapy of ovarian cancer: cyclophosphamide, adriamycin and cisplatin versus 5-fluorouracil, cyclophosphamide and mitomycin C.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1990 |
Comparative study of combination chemotherapy of ovarian cancer: cyclophosphamide, adriamycin and cisplatin versus 5-fluorouracil, cyclophosphamide and mitomycin C.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1990 |
[Hemosorption and polychemotherapy with hyperglycemia in the treatment of ovarian cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Combined Modality T | 1990 |
[Hemosorption and polychemotherapy with hyperglycemia in the treatment of ovarian cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Combined Modality T | 1990 |
Appendiceal adenocarcinoid with ovarian metastasis.
Topics: Adenocarcinoma; Adult; Appendiceal Neoplasms; Female; Fluorouracil; Humans; Ovarian Neoplasms; Strep | 1990 |
Appendiceal adenocarcinoid with ovarian metastasis.
Topics: Adenocarcinoma; Adult; Appendiceal Neoplasms; Female; Fluorouracil; Humans; Ovarian Neoplasms; Strep | 1990 |
[Effects of urinastatin against nephrotoxicity of cisplatinum].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin; Cyclophospham | 1990 |
[Effects of urinastatin against nephrotoxicity of cisplatinum].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin; Cyclophospham | 1990 |
Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Nucleus; Cyclophosphamide; Doxorub | 1990 |
Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Nucleus; Cyclophosphamide; Doxorub | 1990 |
Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Drug Admin | 1990 |
Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Drug Admin | 1990 |
[Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
[Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
[Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1990 |
[Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1990 |
Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Colony-Forming Units Assay; Doxorubicin; Female; Fluorouracil; Folic Acid; Hum | 1990 |
Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Colony-Forming Units Assay; Doxorubicin; Female; Fluorouracil; Folic Acid; Hum | 1990 |
Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line; Cisplatin; Cytarabine; Drug Screening Assa | 1990 |
Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line; Cisplatin; Cytarabine; Drug Screening Assa | 1990 |
Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
Topics: Deoxyuracil Nucleotides; DNA Repair; DNA, Neoplasm; Drug Resistance; Female; Fluorouracil; Humans; O | 1990 |
Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
Topics: Deoxyuracil Nucleotides; DNA Repair; DNA, Neoplasm; Drug Resistance; Female; Fluorouracil; Humans; O | 1990 |
[Transformation of ovarian yolk sac tumor to immature teratoma following chemotherapy].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; | 1985 |
[Transformation of ovarian yolk sac tumor to immature teratoma following chemotherapy].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; | 1985 |
[Chemotherapy of ovarian cancer based on in vitro (HTCA) and in vivo (nude mice) chemosensitivity testing].
Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Colony-Forming Units Assay; Combined Modality | 1985 |
[Chemotherapy of ovarian cancer based on in vitro (HTCA) and in vivo (nude mice) chemosensitivity testing].
Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Colony-Forming Units Assay; Combined Modality | 1985 |
[A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colony-Forming Units Assay; Cycloph | 1985 |
[A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colony-Forming Units Assay; Cycloph | 1985 |
[A case of amylase-producing ovarian tumor].
Topics: Amylases; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma; Cytarabine; Female; Fl | 1986 |
[A case of amylase-producing ovarian tumor].
Topics: Amylases; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma; Cytarabine; Female; Fl | 1986 |
[Changes in CA125 concentration in ovarian cancer patients during the remission state--mean attenuating curve and the effectiveness of surgery and chemotherapy].
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1989 |
[Changes in CA125 concentration in ovarian cancer patients during the remission state--mean attenuating curve and the effectiveness of surgery and chemotherapy].
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1989 |
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc | 1989 |
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc | 1989 |
Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
Topics: Animals; Calmodulin; Carcinoma; Drug Combinations; Drug Synergism; Female; Fluorouracil; Mice; Mice, | 1989 |
Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
Topics: Animals; Calmodulin; Carcinoma; Drug Combinations; Drug Synergism; Female; Fluorouracil; Mice; Mice, | 1989 |
Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones.
Topics: beta-Endorphin; Cell Division; Cystadenocarcinoma; DNA, Neoplasm; Dose-Response Relationship, Drug; | 1989 |
Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones.
Topics: beta-Endorphin; Cell Division; Cystadenocarcinoma; DNA, Neoplasm; Dose-Response Relationship, Drug; | 1989 |
Adenocarcinoma of the small intestine presenting as an ovarian mass. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Femal | 1989 |
Adenocarcinoma of the small intestine presenting as an ovarian mass. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Femal | 1989 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor | 1989 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor | 1989 |
Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1989 |
Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1989 |
[An analysis of factors influential in improving the survival rate of patients with ovarian cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1989 |
[An analysis of factors influential in improving the survival rate of patients with ovarian cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1989 |
[Successful treatment of a patient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hum | 1989 |
[Successful treatment of a patient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hum | 1989 |
[Adjuvant after care of the "small" ovarian cancer (FIGO I): chemotherapy versus radiogold treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; | 1989 |
[Adjuvant after care of the "small" ovarian cancer (FIGO I): chemotherapy versus radiogold treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; | 1989 |
Treatment of advanced ovarian cancer with sequential combination chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1987 |
Treatment of advanced ovarian cancer with sequential combination chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1987 |
[Synchronous double cancers in the ovary and kidney--a case report].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Com | 1988 |
[Synchronous double cancers in the ovary and kidney--a case report].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Com | 1988 |
Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; | 1989 |
Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; | 1989 |
Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Floxuridine; Fluorouracil; Humans; Kinetics; Middle Aged | 1985 |
Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Floxuridine; Fluorouracil; Humans; Kinetics; Middle Aged | 1985 |
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
[Experimental chemotherapy of ovarian cancers heterotransplanted in nude mice].
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1985 |
[Experimental chemotherapy of ovarian cancers heterotransplanted in nude mice].
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1985 |
[Cytostatic treatment of pseudomyxoma peritonei].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; F | 1985 |
[Cytostatic treatment of pseudomyxoma peritonei].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; F | 1985 |
Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo | 1986 |
Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo | 1986 |
Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali | 1986 |
Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali | 1986 |
[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1986 |
[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1986 |
[In vitro effects of 5-FU on gynecologic malignant tumor cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line; Cells, Cultured; Colony-Fo | 1986 |
[In vitro effects of 5-FU on gynecologic malignant tumor cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line; Cells, Cultured; Colony-Fo | 1986 |
[Metastatic brain tumor after chemotherapy of ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Cyclop | 1987 |
[Metastatic brain tumor after chemotherapy of ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Cyclop | 1987 |
[Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1987 |
[Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; | 1987 |
[Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1987 |
[Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1987 |
[Antitumor effect of UFT on human ovarian cancer grafted to nude mice and 5-FU concentration in tumor and normal tissues].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Mi | 1988 |
[Antitumor effect of UFT on human ovarian cancer grafted to nude mice and 5-FU concentration in tumor and normal tissues].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Mi | 1988 |
The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1988 |
The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1988 |
Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |
Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |
The mechanism of acquired resistance to cisplatin by a human ovarian cancer cell line.
Topics: Cell Line; Cisplatin; Drug Resistance; Female; Fluorouracil; Humans; Interphase; Ovarian Neoplasms; | 1988 |
The mechanism of acquired resistance to cisplatin by a human ovarian cancer cell line.
Topics: Cell Line; Cisplatin; Drug Resistance; Female; Fluorouracil; Humans; Interphase; Ovarian Neoplasms; | 1988 |
Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro.
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Dimethyl Sulfoxide; Doxorubicin; Drug Synergism; F | 1988 |
Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro.
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Dimethyl Sulfoxide; Doxorubicin; Drug Synergism; F | 1988 |
Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Division; Cell Line; Cell | 1988 |
Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Division; Cell Line; Cell | 1988 |
Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin.
Topics: Biological Transport; Cell Division; Cell Line; Cisplatin; Drug Resistance; Female; Fluorouracil; Hu | 1988 |
Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin.
Topics: Biological Transport; Cell Division; Cell Line; Cisplatin; Drug Resistance; Female; Fluorouracil; Hu | 1988 |
[Estimation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5-FU concentrations in sera and resected specimens from patients with ovarian tumors].
Topics: Administration, Oral; Female; Fluorouracil; Humans; Ovarian Neoplasms; Ovariectomy; Ovary; Uterus | 1988 |
[Estimation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5-FU concentrations in sera and resected specimens from patients with ovarian tumors].
Topics: Administration, Oral; Female; Fluorouracil; Humans; Ovarian Neoplasms; Ovariectomy; Ovary; Uterus | 1988 |
[A case of leukoencephalopathy caused by HCFU].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; B | 1988 |
[A case of leukoencephalopathy caused by HCFU].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; B | 1988 |
[Treatment of 63 advanced ovarian carcinomas].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1987 |
[Treatment of 63 advanced ovarian carcinomas].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1987 |
Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.
Topics: Carcinoma; Cell Line; Cisplatin; Drug Synergism; Female; Fluorodeoxyuridylate; Fluorouracil; Folic A | 1986 |
Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.
Topics: Carcinoma; Cell Line; Cisplatin; Drug Synergism; Female; Fluorodeoxyuridylate; Fluorouracil; Folic A | 1986 |
Epithelial ovarian cancer. Prolonged relapse-free survival following secondary cytoreductive surgery and intraperitoneal 5-fluorouracil.
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Prognosis | 1987 |
Epithelial ovarian cancer. Prolonged relapse-free survival following secondary cytoreductive surgery and intraperitoneal 5-fluorouracil.
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Prognosis | 1987 |
Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Fluorouracil; Humans; | 1987 |
Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Fluorouracil; Humans; | 1987 |
[Chemotherapy of dysgerminoma].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined | 1987 |
[Chemotherapy of dysgerminoma].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined | 1987 |
[Effect of post operative maintenance chemotherapy against ovarian cancer].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Mice; Mice, | 1987 |
[Effect of post operative maintenance chemotherapy against ovarian cancer].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Mice; Mice, | 1987 |
[Primary cancer of the ovary: anatomoclinical varieties and therapeutic problems in Brazzaville].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1987 |
[Primary cancer of the ovary: anatomoclinical varieties and therapeutic problems in Brazzaville].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1987 |
[Sensitivity of clonogenic cells of human ascitic ovarian cancer to antitumor agents].
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; | 1987 |
[Sensitivity of clonogenic cells of human ascitic ovarian cancer to antitumor agents].
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; | 1987 |
[Consecutive intra-arterial infusion of cis-diamminedichloroplatinum with continuous intra-arterial infusion of 5-fluorouracil in locally advanced ovarian cancer].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sc | 1986 |
[Consecutive intra-arterial infusion of cis-diamminedichloroplatinum with continuous intra-arterial infusion of 5-fluorouracil in locally advanced ovarian cancer].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sc | 1986 |
Adjuvant effects of calmodulin antagonists to 5-fluorouracil on tumor cell proliferation and the mechanisms.
Topics: Adenocarcinoma; Calmodulin; Cell Division; Cell Line; Female; Fluorouracil; Humans; Ovarian Neoplasm | 1987 |
Adjuvant effects of calmodulin antagonists to 5-fluorouracil on tumor cell proliferation and the mechanisms.
Topics: Adenocarcinoma; Calmodulin; Cell Division; Cell Line; Female; Fluorouracil; Humans; Ovarian Neoplasm | 1987 |
[Rare late metastasis of a successfully treated advanced ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cyclopho | 1986 |
[Rare late metastasis of a successfully treated advanced ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cyclopho | 1986 |
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Single agent vs. combination chemotherapy for ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1985 |
Single agent vs. combination chemotherapy for ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1985 |
[Preoperative treatment with UFT for patients with ovarian malignant tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Middle Ag | 1985 |
[Preoperative treatment with UFT for patients with ovarian malignant tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Middle Ag | 1985 |
[In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
Topics: Animals; Antineoplastic Agents; Carbazilquinone; Cell Division; Cell Line; Cell Survival; Cells, Cul | 1985 |
[In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
Topics: Animals; Antineoplastic Agents; Carbazilquinone; Cell Division; Cell Line; Cell Survival; Cells, Cul | 1985 |
Intraperitoneal chemotherapy for advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1985 |
Intraperitoneal chemotherapy for advanced ovarian cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1985 |
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Topics: Adenocarcinoma; Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1985 |
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Topics: Adenocarcinoma; Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1985 |
In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration.
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubici | 1985 |
In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration.
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubici | 1985 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |
Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1985 |
Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1985 |
Treatment of persistent or recurrent ovarian carcinoma with sequential methotrexate and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1986 |
Treatment of persistent or recurrent ovarian carcinoma with sequential methotrexate and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1986 |
[Ribamidil as a modulator of the toxic effect of 5-fluorouracil].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cells, Cultured; DNA, Neoplasm; | 1985 |
[Ribamidil as a modulator of the toxic effect of 5-fluorouracil].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cells, Cultured; DNA, Neoplasm; | 1985 |
Polychemotherapeutic treatment for ovarian carcinoma (our experience).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Dru | 1985 |
Polychemotherapeutic treatment for ovarian carcinoma (our experience).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Dru | 1985 |
The clinical setting and pharmacology of intraperitoneal chemotherapy: an overview.
Topics: Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Female; Fluorouracil; Humans; Infusions, Pa | 1985 |
The clinical setting and pharmacology of intraperitoneal chemotherapy: an overview.
Topics: Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Female; Fluorouracil; Humans; Infusions, Pa | 1985 |
[Effects of chemotherapy of advanced malignant ovarian tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Fluorouracil; Human | 1985 |
[Effects of chemotherapy of advanced malignant ovarian tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Fluorouracil; Human | 1985 |
Multimodal approach to the treatment of stage III ovarian carcinoma: preliminary report of a pilot study and critical review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1985 |
Multimodal approach to the treatment of stage III ovarian carcinoma: preliminary report of a pilot study and critical review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1985 |
[Palliative treatment of ovarian cancers with the association of thiotepa and of 5-fluoro-uracil].
Topics: Adolescent; Adult; Aged; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Palliative Ca | 1971 |
[Palliative treatment of ovarian cancers with the association of thiotepa and of 5-fluoro-uracil].
Topics: Adolescent; Adult; Aged; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Palliative Ca | 1971 |
Malignant gynecologic tumors in children: current approaches to treatment.
Topics: Age Factors; Child; Child, Preschool; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Dysgerminoma; | 1973 |
Malignant gynecologic tumors in children: current approaches to treatment.
Topics: Age Factors; Child; Child, Preschool; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Dysgerminoma; | 1973 |
Chemotherapy and hormone therapy in gynecologic cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Choriocarcinoma; Dactinomycin; F | 1973 |
Chemotherapy and hormone therapy in gynecologic cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Choriocarcinoma; Dactinomycin; F | 1973 |
[The effects of cytostatic agents on short-term cultures (3H-uridine incorporation) and tissue cultures (cell counts) from human tumors (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Cell Count; Cell Transformation, Neoplastic; Cells, Cultured; Cyta | 1974 |
[The effects of cytostatic agents on short-term cultures (3H-uridine incorporation) and tissue cultures (cell counts) from human tumors (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Cell Count; Cell Transformation, Neoplastic; Cells, Cultured; Cyta | 1974 |
Operation, external irradiation, radioactive isotopes, and chemotherapy in treatment of metastatic ovarian malignancies.
Topics: Ascites; Carcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Follow-Up St | 1968 |
Operation, external irradiation, radioactive isotopes, and chemotherapy in treatment of metastatic ovarian malignancies.
Topics: Ascites; Carcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Follow-Up St | 1968 |
Pseudomyxoma peritonaei: a report of ten cases.
Topics: Adenocarcinoma; Adult; Aged; Appendectomy; Appendiceal Neoplasms; Castration; Cystadenoma; Female; F | 1973 |
Pseudomyxoma peritonaei: a report of ten cases.
Topics: Adenocarcinoma; Adult; Aged; Appendectomy; Appendiceal Neoplasms; Castration; Cystadenoma; Female; F | 1973 |
The growth of human tumours in immunosuppressed mice and their response to chemotherapy.
Topics: Animals; Chlorambucil; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Female; Fluorouracil; | 1974 |
The growth of human tumours in immunosuppressed mice and their response to chemotherapy.
Topics: Animals; Chlorambucil; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Female; Fluorouracil; | 1974 |
Interdisciplinary approach to advanced ovarian cancer.
Topics: Alkylating Agents; Ascites; Chlorambucil; Dactinomycin; Drug Therapy, Combination; Female; Fluoroura | 1974 |
Interdisciplinary approach to advanced ovarian cancer.
Topics: Alkylating Agents; Ascites; Chlorambucil; Dactinomycin; Drug Therapy, Combination; Female; Fluoroura | 1974 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Chemotherapy in the treatment of cancer of the ovary.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Cyclophosphamide; Cystadenocarcinoma; Dactinomycin; Female | 1970 |
Chemotherapy in the treatment of cancer of the ovary.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Cyclophosphamide; Cystadenocarcinoma; Dactinomycin; Female | 1970 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
Integrated therapy in the treatment of ovarian cancer with surgery, radiation and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Ascites; Chlorambucil; Cobalt Isotopes; Cyclophosphamide; | 1972 |
Integrated therapy in the treatment of ovarian cancer with surgery, radiation and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Ascites; Chlorambucil; Cobalt Isotopes; Cyclophosphamide; | 1972 |
Chemotherapy of ovarian cancer. New approaches to treatment.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinom | 1972 |
Chemotherapy of ovarian cancer. New approaches to treatment.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinom | 1972 |
Metastatic ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Cyclophosphamide; Cystadenocarcinoma; Dactinomycin; Drug Combinations; Fem | 1973 |
Metastatic ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Cyclophosphamide; Cystadenocarcinoma; Dactinomycin; Drug Combinations; Fem | 1973 |
A second look at the second operation in colonic cancer after the administration of fluorouracil.
Topics: Biopsy; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphat | 1974 |
A second look at the second operation in colonic cancer after the administration of fluorouracil.
Topics: Biopsy; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphat | 1974 |
Observations on chemotherapy of granulosa cell carcinomas and malignant ovarian teratomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Castration; Child; Cyclophosphamide; Dactinomycin; Fallopi | 1974 |
Observations on chemotherapy of granulosa cell carcinomas and malignant ovarian teratomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Castration; Child; Cyclophosphamide; Dactinomycin; Fallopi | 1974 |
[Application of morphological and histochemical methods for evaluation of cytostatic effects on organ cultures of malignant tumors].
Topics: Animals; Antineoplastic Agents; Carcinoma; Culture Techniques; Female; Fluorouracil; Histocytochemis | 1974 |
[Application of morphological and histochemical methods for evaluation of cytostatic effects on organ cultures of malignant tumors].
Topics: Animals; Antineoplastic Agents; Carcinoma; Culture Techniques; Female; Fluorouracil; Histocytochemis | 1974 |
Acute leukemia following cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Methotrexate; Ovarian | 1972 |
Acute leukemia following cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Methotrexate; Ovarian | 1972 |
[Testing the sensitivity of tumors to chemotherapeutic preparations on surviving sections].
Topics: Female; Fluorouracil; Humans; In Vitro Techniques; Ovarian Neoplasms; Thiotepa | 1972 |
[Testing the sensitivity of tumors to chemotherapeutic preparations on surviving sections].
Topics: Female; Fluorouracil; Humans; In Vitro Techniques; Ovarian Neoplasms; Thiotepa | 1972 |
Incubation of surviving sections of ovarian tumours as a method of testing their sensitivity to cytostatics.
Topics: Culture Techniques; DNA, Neoplasm; Female; Fluorouracil; Humans; Melphalan; Nitrogen Mustard Compoun | 1972 |
Incubation of surviving sections of ovarian tumours as a method of testing their sensitivity to cytostatics.
Topics: Culture Techniques; DNA, Neoplasm; Female; Fluorouracil; Humans; Melphalan; Nitrogen Mustard Compoun | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
[Experiences on in vitro testing of cytostatic sensitivity (oncobiogram) in gynecological tumors].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Resistance; Female; Fluorouracil; Genital Neoplasms, F | 1973 |
[Experiences on in vitro testing of cytostatic sensitivity (oncobiogram) in gynecological tumors].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Resistance; Female; Fluorouracil; Genital Neoplasms, F | 1973 |
Gynecologic oncology.
Topics: Alkylating Agents; Ascites; Biopsy; Dactinomycin; Endometrium; Female; Fluorouracil; Genital Neoplas | 1973 |
Gynecologic oncology.
Topics: Alkylating Agents; Ascites; Biopsy; Dactinomycin; Endometrium; Female; Fluorouracil; Genital Neoplas | 1973 |
The value of chemotherapy in the irradiation of ovarian carcinoma.
Topics: Chlorambucil; Cobalt Isotopes; Female; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intr | 1966 |
The value of chemotherapy in the irradiation of ovarian carcinoma.
Topics: Chlorambucil; Cobalt Isotopes; Female; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intr | 1966 |
Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ova | 1967 |
Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ova | 1967 |
[Antineoplastic polychemotherapy in thoracic pathology].
Topics: Adrenalectomy; Aged; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cortisone; Cyclop | 1968 |
[Antineoplastic polychemotherapy in thoracic pathology].
Topics: Adrenalectomy; Aged; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cortisone; Cyclop | 1968 |
Cytotoxic agents in the treatment of malignant disease.
Topics: Antimetabolites; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chlorambucil; Choriocarcinoma; | 1968 |
Cytotoxic agents in the treatment of malignant disease.
Topics: Antimetabolites; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chlorambucil; Choriocarcinoma; | 1968 |
[On selection of antineoplastic agents for local use].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; In Vitro Techniques; | 1969 |
[On selection of antineoplastic agents for local use].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; In Vitro Techniques; | 1969 |
[Effect of thiophosphamide and 5-fluorouracil on the incorporation of H 3-thymidine into DNA of surviving ovarian cancer sections].
Topics: Culture Techniques; Depression, Chemical; DNA, Neoplasm; Female; Fluorouracil; Humans; Ovarian Neopl | 1971 |
[Effect of thiophosphamide and 5-fluorouracil on the incorporation of H 3-thymidine into DNA of surviving ovarian cancer sections].
Topics: Culture Techniques; Depression, Chemical; DNA, Neoplasm; Female; Fluorouracil; Humans; Ovarian Neopl | 1971 |
[Combined cytostatic treatment of ovarian cancer].
Topics: Adult; Aged; Drug Synergism; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Middle Aged; | 1972 |
[Combined cytostatic treatment of ovarian cancer].
Topics: Adult; Aged; Drug Synergism; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Middle Aged; | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem | 1972 |
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem | 1972 |
5-fluorouracil given once weekly: comparison of intravenous and oral administration.
Topics: Adenocarcinoma; Administration, Oral; Biliary Tract Diseases; Breast Neoplasms; Female; Fluorouracil | 1971 |
5-fluorouracil given once weekly: comparison of intravenous and oral administration.
Topics: Adenocarcinoma; Administration, Oral; Biliary Tract Diseases; Breast Neoplasms; Female; Fluorouracil | 1971 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
Embryonal cell carcinoma of the ovary. Report of a case.
Topics: Abdominal Neoplasms; Adolescent; Age Factors; Black People; Cyclophosphamide; Drug Therapy, Combinat | 1971 |
Embryonal cell carcinoma of the ovary. Report of a case.
Topics: Abdominal Neoplasms; Adolescent; Age Factors; Black People; Cyclophosphamide; Drug Therapy, Combinat | 1971 |
Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
Topics: Adolescent; Adult; Aged; Antigens; Antineoplastic Agents; Breast Neoplasms; Candida; Child; Child, P | 1970 |
Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
Topics: Adolescent; Adult; Aged; Antigens; Antineoplastic Agents; Breast Neoplasms; Candida; Child; Child, P | 1970 |
Solid malignant ovarian teratoma: case of an 8 year survival.
Topics: Adult; Castration; Colon; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Ileum; Inje | 1971 |
Solid malignant ovarian teratoma: case of an 8 year survival.
Topics: Adult; Castration; Colon; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Ileum; Inje | 1971 |
Observations on gynecologic malignancy treated with 5-fluorouracil.
Topics: Adult; Age Factors; Aged; Fallopian Tube Neoplasms; Female; Fluorouracil; Genital Neoplasms, Female; | 1968 |
Observations on gynecologic malignancy treated with 5-fluorouracil.
Topics: Adult; Age Factors; Aged; Fallopian Tube Neoplasms; Female; Fluorouracil; Genital Neoplasms, Female; | 1968 |
[Antitumor polychemotherapy].
Topics: Adult; Antimetabolites; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Chlorambucil; | 1968 |
[Antitumor polychemotherapy].
Topics: Adult; Antimetabolites; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Chlorambucil; | 1968 |
Treatment of cancer with weekly intravenous 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, | 1968 |
Treatment of cancer with weekly intravenous 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, | 1968 |
[Comparative study of sequential or combined therapy with cyclophosphamide and 5-fluorouracil in adenocarcinoma of the breast and ovary].
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Ovarian Neoplasms | 1968 |
[Comparative study of sequential or combined therapy with cyclophosphamide and 5-fluorouracil in adenocarcinoma of the breast and ovary].
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Ovarian Neoplasms | 1968 |
[Treatment of patients with cancer of the ovary with 5-fluorouracil].
Topics: Female; Fluorouracil; Humans; Ovarian Neoplasms | 1969 |
[Treatment of patients with cancer of the ovary with 5-fluorouracil].
Topics: Female; Fluorouracil; Humans; Ovarian Neoplasms | 1969 |
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T | 1965 |
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T | 1965 |